Document:

<Page>

                                                                   EXHIBIT 10.16

                              EMPLOYMENT AGREEMENT

     This Employment Agreement ("AGREEMENT") is made and entered into on this
9th day of April, 2001, effective as of April 1, 2001 by and between AMERIPATH,
INC., a Delaware corporation (the "COMPANY"), and GREGORY A. MARSH (hereinafter,
the "EXECUTIVE").

                                 R E C I T A L S

     A.   The Executive is currently employed by the Company as its Vice
President and Chief Financial Officer pursuant to a letter agreement dated
February 1, 2001 (the "PRIOR EMPLOYMENT AGREEMENT").

     B.   Prior to entering into the Prior Employment Agreement, the Company
offered the Executive and the Executive accepted an Executive Retention
Agreement dated August 12, 1999 (the "Retention Agreement").

     C.   The Company and the Executive now wish to enter into this new
Agreement, which is intended to supercede and replace the Prior Employment
Agreement and the Retention Agreement in their entirety, to reflect the
Executive's position and duties, his compensation, and other terms and
conditions of his employment as Vice President and Chief Financial Officer of
the Company. Upon execution of this Agreement by both the Executive and the
Company, the Prior Employment Agreement and the Retention Agreement shall
terminate and no longer have any force and effect.

                                    AGREEMENT

     NOW, THEREFORE, in consideration of the promises and mutual covenants set
forth herein and other good and valuable consideration, the receipt and
sufficiency of which is hereby acknowledged, the Executive and the Company agree
as follows:

     1.   RECITALS. The foregoing recitals are true and correct and are
incorporated herein by this reference.

     2.   EMPLOYMENT.

          2.1   EMPLOYMENT AND TERM. During the Term of Employment, the Company
hereby agrees to employ the Executive and the Executive hereby agrees to serve
the Company on the terms and conditions set forth herein.

          2.2   DUTIES OF EXECUTIVE. During the Term of Employment, the
Executive shall serve as the Vice President and Chief Financial Officer of the
Company, shall faithfully and diligently perform all services as may be assigned
to him by the Company, and shall exercise such power and authority as may from
time to time be delegated to him. The Executive shall devote his full time and
attention to the business and affairs of the Company, render such services to
the best of his ability, and use his reasonable best efforts to promote the
interests of

                                      - 1 -
<Page>

the Company. The Executive shall comply with the Company's employment policies
and practices generally applicable to its officers and employees including,
without limitation, insider trading and confidentiality policies.
Notwithstanding the foregoing or any other provision of this Agreement, it shall
not be a breach or violation of this Agreement for the Executive to (i) serve on
corporate, civic or charitable boards or committees, (ii) deliver lectures,
fulfill speaking engagements or teach at educational institutions, or (iii)
manage personal investments, so long as such activities do not interfere with or
detract from the performance of the Executive's responsibilities to the Company
in accordance with this Agreement.

     3.   TERM OF EMPLOYMENT. The term of employment under this Agreement, and
the employment of the Executive hereunder (the "TERM OF EMPLOYMENT"), shall
commence upon execution of this Agreement by both the Executive and the Company
and shall terminate upon the date on which the employment of the Executive is
terminated pursuant to and in accordance with Section 6 hereof (the "EXPIRATION
DATE").

     4.   COMPENSATION.

          4.1   BASE SALARY. The Executive shall receive a base salary at the
annual rate of $180,000 (the "BASE SALARY") during the Term of Employment, with
such Base Salary payable in installments consistent with the Company's normal
payroll schedule, subject to applicable withholding and other taxes. The Base
Salary shall be reviewed at least annually.

          4.2   BONUSES.

                a.  During the Term of Employment, for each calendar year during
the Term of Employment (the "Bonus Period"), the Board shall establish a bonus
pool from which the Executive shall be eligible to receive an annual bonus
potentially equal to thirty-five percent (35%) of the Executive's Base Salary
(the "BONUS PAYMENT"), to be determined by the Executive's supervisor and based
upon the satisfaction by the Executive and/or the Company of the goals (the
"GOALS"), to be established by the Company. Notwithstanding the foregoing, in
the event that the Goals are either exceeded or not fully achieved for a Bonus
Period, the Executive may be eligible to receive a Bonus Payment in an amount in
excess of or less than thirty-five percent (35%) of the Executive's Base Salary.

                b.  For the Bonus Period in which the Executive's employment
with the Company terminates for any reason other than by the Company for Cause
under Section 6.1 hereof, provided that the Executive has been continuously
employed with the Company for a minimum of six (6) months during such Bonus
Period, the Company shall pay the Executive a pro rata portion (based upon the
period beginning on the first day of the Bonus Period and ending on the date on
which the Executive's employment with the Company terminates) of the bonus
otherwise payable under Section 4.2 for the Bonus Period in which such
termination of employment occurs; provided, however, that (i) the Bonus Period
shall be deemed to end on the last day of the calendar quarter in which the
Executive's employment so terminates, and (ii) the business criteria used to
determine the bonus for this short Bonus Period shall be annualized and

                                      - 2 -
<Page>

shall be determined based upon audited financial information prepared in
accordance with generally accepted accounting principles, applied consistently
with prior periods, and reviewed and approved by the Compensation Committee of
the Board. The Incentive Compensation for this Bonus Period is sometimes
hereinafter referred to as the "TERMINATION YEAR BONUS".

     5.   EXPENSE REIMBURSEMENT AND OTHER BENEFITS.

          5.1   REIMBURSEMENT OF EXPENSES. Upon the submission of proper
substantiation by the Executive, and subject to such rules and guidelines as the
Company may from time to time adopt with respect to the reimbursement of
expenses of executive personnel, the Company shall reimburse the Executive for
all reasonable expenses actually paid or incurred by the Executive during the
Term of Employment in the course of and pursuant to the business of the Company.
The Executive shall account to the Company in writing for all expenses for which
reimbursement is sought and shall supply to the Company copies of all relevant
invoices, receipts or other evidence reasonably requested by the Company.

          5.2   COMPENSATION/BENEFIT PROGRAMS. During the Term of Employment,
the Executive shall be entitled to participate in all medical, dental,
hospitalization, accidental death and dismemberment, disability, travel and life
insurance plans, and any and all other plans as are presently and hereinafter
offered by the Company to its executive personnel, including savings, pension,
profit-sharing and deferred compensation plans, subject to the general
eligibility and participation provisions set forth in such plans.

          5.3   STOCK OPTIONS. During the Term of Employment hereunder, and
subject to the execution of any other applicable agreements, the Executive shall
be eligible on an annual basis to receive options (the "STOCK OPTIONS") to
purchase common stock (the "COMMON STOCK") of the Company, the amount to be
determined by the Chairman of the Board and CEO (the "CHAIRMAN") of the Company
based upon the Executive's performance and services rendered to the Company, and
subject to the approval by both the Compensation Committee and the Board at
their regular annual review of executive performance. If and to the extent
awarded, the Stock Options shall be granted under (and therefore subject to all
terms of) the Company's stock option plan (the "STOCK OPTION PLAN") and pursuant
to the terms of a certain stock option agreement (the "OPTION AGREEMENT") to be
entered into by and between the Executive and the Company. In addition, during
the Term of Employment, the Executive shall be eligible to be granted additional
options under the Company's Stock Option Plan. The number, if any, of additional
options and terms and conditions thereof shall be determined by the Committee
appointed pursuant to the Stock Option Plan, or by the Board of Directors of the
Company, in its discretion and pursuant to the Stock Option Plan.
Notwithstanding any other provision of this Agreement, Option Agreements entered
into by the Executive and the Company prior to the date of this Agreement shall
remain in full force and effect.

          5.4   OTHER BENEFITS. The Executive shall accrue up to four (4) weeks
of paid vacation each calendar year during the Term of Employment, to be taken
at such times as the Executive and the Company shall mutually determine and
provided that no vacation time shall

                                      - 3 -
<Page>

significantly interfere with the duties required to be rendered by the Executive
hereunder. Any accrued vacation time not taken by Executive during any calendar
year may be carried forward into any succeeding calendar year. Notwithstanding
the foregoing, in no event shall the Executive's accrued vacation time exceed
four (4) weeks at any point in time. The Executive shall receive such additional
benefits, if any, as the Board of the Company shall from time to time determine.

     6.   TERMINATION AND/OR CHANGE OF CONTROL.

          6.1   TERMINATION FOR CAUSE. The Company shall at all times have the
right, upon written notice to the Executive, to terminate the Term of
Employment, for Cause as defined below. For purposes of this Agreement, the term
"CAUSE" shall mean (i) an action or omission of the Executive which constitutes
a willful and material breach of, or willful and material failure or refusal
(other than by reason of his disability or incapacity) to perform his duties
under, this Agreement which is not cured within fifteen (15) days after receipt
by the Executive of written notice of same, (ii) fraud, embezzlement,
misappropriation of funds or breach of trust in connection with his services
hereunder, (iii) a conviction of any crime which involves dishonesty or a breach
of trust, or (iv) gross negligence in connection with the performance of the
Executive's duties hereunder, which the Board in its reasonable discretion deems
to be good and sufficient cause to terminate the Executive's employment with the
Company. Any termination for Cause shall be made by notice in writing to the
Executive, which notice shall set forth in reasonable detail all acts or
omissions upon which the Company is relying for such termination. Upon any
termination pursuant to this Section 6.1, the Company shall pay to the Executive
any accrued and unpaid Base Salary through the date of termination. Upon any
termination effected and compensated pursuant to this Section 6.1, the Company
shall have no further liability hereunder (other than for reimbursement for
reasonable business expenses incurred prior to the date of termination, subject,
however, to the provisions of Section 5.1, and payment of compensation for
accrued and unused vacation days).

          6.2   DISABILITY. The Company shall at all times have the right, upon
written notice to the Executive, to terminate the Term of Employment, if the
Executive shall become entitled to benefits under the Company's long term
disability plan as then in effect, or, if the Executive shall as the result of
mental or physical incapacity, illness or disability, become unable to perform
his obligations hereunder for a period of 180 days in any 12-month period. The
Board shall have sole discretion based upon competent medical advice to
determine whether the Executive is or continues to be disabled. Upon any
termination pursuant to this Section 6.2, the Company shall (i) pay to the
Executive any accrued and unpaid Base Salary and Bonus Payment, through the
effective date of termination specified in such notice, (ii) pay to the
Executive his Termination Year Bonus, if any, at the time provided in Section
4.2b hereof, and (iii) pay the COBRA premiums for the Executive's medical and
dental insurance coverage in effect on the termination date, for a period of
twelve (12) months following the termination of the Executive's employment with
the Company. Upon any termination effected and compensated pursuant to this
Section 6.2, the Company shall have no further liability hereunder (other than
for reimbursement for reasonable business expenses incurred prior to the date of
termination,

                                      - 4 -
<Page>

subject, however, to the provisions of Section 5.1, and payment of compensation
for accrued and unused vacation days).

          6.3   DEATH. Upon the death of the Executive during the Term of
Employment, the Company shall (i) pay to the estate of the deceased Executive
any accrued and unpaid Base Salary and Bonus Payment, through the Executive's
date of death, (ii) pay to the estate of the deceased Executive, the Executive's
Termination Year Bonus, if any, at the time provided in Section 4.2b hereof.
Upon any termination effected and compensated pursuant to this Section 6.3, the
Company shall have no further liability hereunder (other than for reimbursement
for reasonable business expenses incurred prior to the date of termination,
subject, however, to the provisions of Section 5.1, and payment of compensation
for accrued and unused vacation days).

          6.4   TERMINATION WITHOUT CAUSE. At any time the Company shall have
the right to terminate the Term of Employment by written notice to the
Executive. Upon any termination pursuant to this Section 6.4 (that is not a
termination under any of Sections 6.1, 6.2, 6.3 or 6.5) the Company shall (i)
pay to the Executive any accrued and unpaid Base Salary and Bonus Payment,
through the date of termination specified in such notice, (ii) continue to pay
the Executive's Base Salary for a period of twelve (12) months following the
termination of the Executive's employment with the Company, in the manner and at
such times as the Base Salary otherwise would have been payable to the
Executive, (iii) pay to the Executive his Termination Year Bonus, if any, at the
time provided in Section 4.2b, and (iv) pay the COBRA premiums for the
Executive's medical and dental insurance coverage in effect on the termination
date, for a period of twelve (12) months following the termination of the
Executive's employment with the Company. Upon any termination effected and
compensated pursuant to this Section 6.4, the Company shall have no further
liability hereunder (other than for reimbursement for reasonable business
expenses incurred prior to the date of termination, subject, however, to the
provisions of Section 5.1, and payment of compensation for accrued and unused
vacation days).

          6.5   TERMINATION BY EXECUTIVE.

                a.  The Executive shall at all times have the right, by written
notice not less than ninety (90) days prior to the termination date, to
terminate his Employment Term.

                b.  Upon termination of the Term of Employment pursuant to this
Section 6.5 (that is not a termination under Section 6.6) by the Executive, the
Company shall pay to the Executive any accrued and unpaid Base Salary and Bonus
Payment, through the effective date of termination specified in such notice.
Upon any termination effected and compensated pursuant to this Section 6.5, the
Company shall have no further liability hereunder (other than for reimbursement
for reasonable business expenses incurred prior to the date of termination,
subject, however, to the provisions of Section 5.1, and payment of compensation
for accrued and unused vacation days).

                                      - 5 -
<Page>

          6.6   CHANGE IN CONTROL OF THE COMPANY.

                a.  Unless otherwise provided in Section 6.7 hereof, in the
event that a Change in Control (as defined in paragraph g. of this Section 6.6)
in the Company shall occur during the Term of Employment, the Company shall (i)
pay to the Executive, within thirty (30) days of the date of the Change in
Control, a lump sum bonus equal to one and one half times the Executive's annual
Base Salary (the "Change in Control Date Bonus"), and (ii) the vesting of all
AmeriPath Stock Options which have been granted to the Executive but are
unvested, so that the unvested shares are one hundred (100) percent vested on
the date of Change in Control.

                b.  If the Executive's Term of Employment is terminated prior to
and it is reasonably demonstrated that such termination (i) was at the request
of a third party who has taken steps reasonably calculated to effect a Change of
Control, or (ii) otherwise arose in connection with or anticipation of a Change
of Control, then for all purposes hereunder, a "Change of Control Termination"
shall be deemed to have occurred.

                c.  If Executive's Term of Employment is terminated without
cause pursuant Section 6.4 hereof, within one year after a Change of Control, a
"Change of Control Termination" shall be deemed to have occurred.

                d.  If, within one year following a Change of Control, (i) the
Company requires the Executive to be based at any office or location more than
twenty-five (25) miles from that in which the Executive was based at the time
this Agreement was executed (except for travel reasonably required in the
performance of the Executive's duties and responsibilities hereunder), or (ii)
the Executive's position (including status, offices, titles and reporting
requirements), authority, duties and responsibilities are not at least
commensurate in all material respects with the most significant of those held,
exercised and assigned at the time preceding the Change in Control, then in
either event, the Executive may elect to terminate this Agreement and a "Change
of Control Termination" shall be deemed to have occurred.

                e.  In the event of a "Change of Control Termination" under
paragraphs b, c, or d of this Section 6.6, the Company shall:

                    (i)    pay to the Executive any accrued and unpaid Base
Salary and Bonus Payment, through the effective date of the termination;

                    (ii)   pay to the Executive his Termination Year Bonus, if
any, at the time provided in Section 4.2b hereof;

                    (iii)  pay to the Executive, within 30 days of the
termination of his employment hereunder, a lump sum payment equal to one and one
half times the Executive's annual Base Salary;

                                      - 6 -
<Page>

                    (iv)   accelerate the vesting of all AmeriPath Stock Options
which have been granted to the Executive since the Change in Control but are
unvested, so that the unvested shares are one hundred (100) percent vested as of
the Executive's Termination Date; and

                    (v)    pay to the Executive in a lump sum the compensation
and benefits provided in the Termination Without Cause Section 6.4.

The Company shall have no further liability hereunder (other than for
reimbursement for reasonable business expenses incurred prior to the date of
termination, subject, however, to the provisions of Section 5.1, and payment of
compensation for accrued and unused vacation days).

                f.  If, on the date of the one-year anniversary of the date of
the Change In Control, the Executive is in the employ of the Company, or any
successor thereto or assign thereof, the Executive shall be paid, on such
one-year anniversary date, an additional lump sum bonus equal to one (1) times
the Executive's annual Base Salary as determined immediately prior to the Change
in Control Date (the "Anniversary Bonus").

                g.  For purposes of this Agreement, the term "CHANGE IN CONTROL"
shall mean:

                    (i)    Approval by the shareholders of the Company of (x) a
reorganization, merger, consolidation or other form of corporate transaction or
series of transactions, in each case, with respect to which persons who were the
shareholders of the Company immediately prior to such reorganization, merger or
consolidation or other transaction do not, immediately thereafter, own more than
50% of the combined voting power entitled to vote generally in the election of
directors of the reorganized, merged or consolidated company's then outstanding
voting securities, in substantially the same proportions as their ownership
immediately prior to such reorganization, merger, consolidation or other
transaction, or (y) a liquidation or dissolution of the Company or (z) the sale
of all or substantially all of the assets of the Company (unless such
reorganization, merger, consolidation or other corporate transaction,
liquidation, dissolution or sale is subsequently abandoned);

                    (ii)   Individuals who, as of the Commencement Date of this
Agreement, constitute the Board (the "INCUMBENT BOARD") cease for any reason to
constitute at least a majority of the Board, provided that any person becoming a
director subsequent to the Commencement Date of this Agreement whose election,
or nomination for election by the Company's shareholders, was approved by a vote
of at least a majority of the directors then comprising the Incumbent Board
(other than an election or nomination of an individual whose initial assumption
of office is in connection with an actual or threatened election contest
relating to the election of the Directors of the Company) shall be, for purposes
of this Agreement, considered as though such person were a member of the
Incumbent Board; or

                                      - 7 -
<Page>

                    (iii)  the acquisition (other than by or from the Company)
by any person, entity or "group", within the meaning of Section 13(d)(3) or
14(d)(2) of the Securities Exchange Act, of beneficial ownership within the
meaning of Rule 13-d promulgated under the Securities Exchange Act of 50% or
more of either the then outstanding shares of the Company's Common Stock or the
combined voting power of the Company's then outstanding voting securities
entitled to vote generally in the election of directors [(hereinafter referred
to as the ownership of a "CONTROLLING INTEREST") excluding, for this purpose,
any acquisitions by (1) the Company or its Subsidiaries, (2) any person, entity
or "group" that as of the Commencement Date of this Agreement owns beneficial
ownership (within the meaning of Rule 13d-3 promulgated under the Securities
Exchange Act) of a Controlling Interest or (3) any employee benefit plan of the
Company or its Subsidiaries].

          6.7   CERTAIN REDUCTION OF PAYMENTS BY THE COMPANY.

                a.  For purposes of this section, (i) A PAYMENT shall mean any
payment or distribution in the nature of compensation to or for the benefit of
the Executive, whether paid or payable pursuant to this Agreement or otherwise;
(ii) AGREEMENT PAYMENT shall mean a Payment paid or payable pursuant to this
Agreement (disregarding this Section 6.7); (iii) NET AFTER TAX RECEIPT shall
mean the Present Value of a Payment net of all taxes imposed on the Executive
with respect thereto under Sections 1 and 4999 of the Code, determined by
applying the highest marginal rate under Section 1 of the Code which applied to
the Executive's taxable income for the immediately preceding taxable year; (iv)
"PRESENT VALUE" shall mean such value determined in accordance with Section
280G(d)(4) of the Code; and (v) "REDUCED AMOUNT" shall mean the smallest
aggregate amount of Payments which (a) is less than the sum of all Payments and
(b) results in aggregate Net After Tax Receipts which are equal to or greater
than the Net After Tax Receipts which would result if the aggregate Payments
were any other amount equal to or less than the sum of all Payments.

                b.  Anything in this Agreement to the contrary notwithstanding,
in the event that the Company's independent auditors or, at the Executive's
option, any other nationally or regionally recognized firm of independent
accountants selected by the Executive and approved by the Company, which
approval shall not be unreasonably withheld (the "ACCOUNTING FIRM"), shall
determine that receipt of all Payments would subject the Executive to tax under
Section 4999 of the Code, it shall determine whether some amount of Payments
would meet the definition of a "REDUCED AMOUNT." If the Accounting Firm
determines that there is a Reduced Amount, the aggregate Agreement Payments
shall be reduced to such Reduced Amount; provided, however, that if the Reduced
Amount exceeds the aggregate Agreement Payments, the aggregate Payments shall,
after the reduction of all Agreement Payments, be reduced (but not below zero)
in the amount of such excess.

                c.  If the Accounting Firm determines that aggregate Agreement
Payments or Payments, as the case may be, should be reduced to the Reduced
Amount, the Company shall promptly give the Executive notice to that effect and
a copy of the detailed calculation thereof, and the Executive may then elect, in
his sole discretion, which and how much

                                      - 8 -
<Page>

of the Agreement Payments or Payments, as the case may be, shall be eliminated
or reduced (as long as after such election the present value of the aggregate
Payments equals the Reduced Amount), and shall advise the Company in writing of
his election within ten days of his receipt of notice. If no such election is
made by the Executive within such ten-day period, the Company may elect which of
the Agreement Payments or Payments, as the case may be, shall be eliminated or
reduced (as long as after such election the present value of the aggregate
Payments equals the Reduced Amount) and shall notify the Executive promptly of
such election. All determinations made by the Accounting Firm under this Section
shall be binding upon the Company and the Executive and shall be made within 60
days of a termination of employment of the Executive. As promptly as practicable
following such determination, the Company shall pay to or distribute for the
benefit of the Executive such Payments as are then due to the Executive under
this Agreement and shall promptly pay to or distribute for the benefit of the
Executive in the future such Payments as become due to the Executive under this
Agreement.

                d.  While it is the intention of the Company and the Executive
to reduce the amounts payable or distributable to the Executive hereunder only
if the aggregate Net After Tax Receipts to the Executive would thereby be
increased, as a result of the uncertainty in the application of Section 4999 of
the Code at the time of the initial determination by the Accounting Firm
hereunder, it is possible that amounts will not have been paid or distributed by
the Company to or for the benefit of the Executive pursuant to this Agreement
which should not have been so paid or distributed ("OVERPAYMENT") or that
additional amounts which will have not been paid or distributed by the Company
to or for the benefit of the Executive pursuant to this Agreement could have
been so paid or distributed ("UNDERPAYMENT"), in each case, consistent with the
calculation of the Reduced Amount hereunder. In the event that the Accounting
Firm, based either upon the assertion of a deficiency by the Internal Revenue
Service against the Company or the Executive which the Accounting Firm believes
has a high probability of success or controlling precedent or other substantial
authority, determines that an Overpayment has been made, any such Overpayment
paid or distributed by the Company to or for the benefit of the Executive shall
be treated for all purposes as a loan AB INITIO to the Executive which the
Executive shall repay to the Company together with interest at the applicable
federal rate provided for in Section 7872(f)(2) of the Code; provided, however,
that no loan shall be deemed to have been made and no amount shall be payable by
the Executive to the Company if and to the extent such deemed loan and payment
would not either reduce the amount on which the Executive is subject to tax
under Section 1 and Section 4999 of the Code or generate a refund of such taxes.
In the event that the Accounting Firm, based upon controlling precedent or other
substantial authority, determines that an Underpayment has occurred, any such
Underpayment shall be promptly paid by the Company to or for the benefit of the
Executive together with interest at the applicable federal rate provided for in
Section 7872(f)(2) of the Code.

          6.8   RESIGNATION. Upon any termination of employment pursuant to this
Article 6, the Executive shall be deemed to have resigned as an officer, and if
he was then serving as a director of the Company, as a director, and if required
by the Board, the Executive hereby agrees to immediately execute a resignation
letter to the Board.

                                      - 9 -
<Page>

          6.9   SURVIVAL. The provisions of this Article 6 shall survive the
termination of this Agreement, as applicable.

     7.   RESTRICTIVE COVENANTS.

          7.1   NON-COMPETITION. At all times while the Executive is employed by
the Company and for a one (1) year period immediately following the termination
of the Executive's employment with the Company for any reason, the Executive
shall not, directly or indirectly, engage in or have any interest in any sole
proprietorship, corporation, company, partnership, association, venture or
business or any other person or entity (whether as an employee, officer,
director, partner, agent, security holder, creditor, consultant or otherwise)
that directly or indirectly (or through any affiliated entity) competes with the
Company's business (for purposes of this Agreement, any business that engages in
the management or provision of anatomic pathology diagnostic services {whether
through physician practices, laboratories, hospitals, medical or surgery centers
or otherwise} shall be deemed to compete with the Company's business); provided
that such provision shall not apply to the Executive's ownership of common stock
of the Company or the acquisition by the Executive, solely as an investment, of
securities of any issuer that are registered under Section 12(b) or 12(g) of the
Securities Exchange Act of 1934, as amended, and that are listed or admitted for
trading on any United States national securities exchange or that are quoted on
the National Association of Securities Dealers Automated Quotations System, or
any similar system or automated dissemination of quotations of securities prices
in common use, so long as the Executive does not control, acquire a controlling
interest in or become a member of a group which exercises direct or indirect
control of, more than five percent (5.0%) of any class of capital stock of such
corporation.

          7.2   CONFIDENTIAL INFORMATION. The Executive shall not at any time
divulge, communicate, use to the detriment of the Company or for the benefit of
any other person or persons, or misuse in any way, any Confidential Information
(as hereinafter defined) pertaining to the business of the Company. Any
Confidential Information or data now or hereafter acquired by the Executive with
respect to the business of the Company (which shall include, but not be limited
to, information concerning the Company's financial condition, prospects,
technology, customers, suppliers, employees, employee compensation or benefits,
employment practices and methods of doing business) shall be deemed a valuable,
special and unique asset of the Company that is received by the Executive in
confidence and as a fiduciary, and Executive shall remain a fiduciary to the
Company with respect to all of such information. For purposes of this Agreement,
"CONFIDENTIAL INFORMATION" means information disclosed to the Executive or known
by the Executive as a consequence of or through the unique position of his
employment with the Company (including information conceived, originated,
discovered or developed by the Executive) prior to or after the date hereof, and
not generally or publicly known, about the Company or its business.
Notwithstanding the foregoing, nothing herein shall be deemed to restrict the
Executive from disclosing Confidential Information to promote the best interests
of the Company or to the extent required by law.

                                     - 10 -
<Page>

          7.3   NONSOLICITATION OF EMPLOYEES AND CUSTOMERS. At all times while
the Executive is employed by the Company and for the two (2) year period
immediately following the termination of the Executive's employment with the
Company for any reason, the Executive shall not, directly or indirectly, for
himself or for or on behalf of any other person, firm, corporation, partnership,
association or other entity (a) employ or attempt to employ or solicit the
termination of employment of or enter into any contractual arrangement with any
employee or former employee of the Company, unless such employee or former
employee has not been employed by the Company for a period in excess of six (6)
months, and/or (b) call on or solicit any of the actual or targeted prospective
customers or clients of the Company (or of its physician practices or
laboratories) on behalf of any person or entity in connection with any business
that competes with the Company's business, nor shall the Executive make known
the names and/or addresses of such employees, customers or clients or any
information relating in any manner to the Company's trade or business
relationships with such employees, customers or clients, other than in
connection with the performance of Executive's duties under this Agreement.

          7.4   OWNERSHIP OF DEVELOPMENTS. All copyrights, patents, trade
secrets, or other intellectual property rights associated with any ideas,
concepts, techniques, inventions, processes, or works of authorship developed or
created by Executive during the course of performing work for the Company or its
clients (collectively, the "WORK PRODUCT") shall belong exclusively to the
Company and shall, to the extent possible, be considered a work made by the
Executive for hire for the Company within the meaning of Title 17 of the United
States Code. To the extent the Work Product may not be considered work made by
the Executive for hire for the Company, the Executive agrees to assign, and
automatically assign at the time of creation of the Work Product, without any
requirement of further consideration, any right, title, or interest the
Executive may have in such Work Product. Upon the request of the Company, the
Executive shall take such further actions, including execution and delivery of
instruments of conveyance, as may be appropriate to give full and proper effect
to such assignment.

          7.5   BOOKS AND RECORDS. All books, records, and accounts relating in
any manner to the customers or clients of the Company, whether prepared by the
Executive or otherwise coming into the Executive's possession, shall be the
exclusive property of the Company and shall be returned immediately to the
Company on termination of the Executive's employment hereunder or on the
Company's request at any time.

          7.6   DEFINITION OF COMPANY. Solely for purposes of this Article 7,
the term "COMPANY" also shall include any existing or future subsidiaries of the
Company that are operating during the time periods described herein and any
other entities that directly or indirectly, through one or more intermediaries,
control, are controlled by or are under common control with the Company during
the periods described herein.

          7.7   ACKNOWLEDGMENT BY EXECUTIVE. The Executive acknowledges and
confirms that (a) the restrictive covenants contained in this Article 7 are
reasonably necessary to protect the legitimate business interests of the
Company, and (b) the restrictions contained in this Article 7 (including without
limitation the length of the term of the provisions of this Article 7)

                                     - 11 -
<Page>

are not overbroad, overlong, or unfair and are not the result of overreaching,
duress or coercion of any kind. The Executive acknowledges and confirms that
his special knowledge of the business of the Company is such as would cause the
Company serious injury or loss if he were to use such ability and knowledge to
the benefit of a competitor or were to compete with the Company in violation of
the terms of this Article 7. The Executive further acknowledges that the
restrictions contained in this Article 7 are intended to be, and shall be, for
the benefit of and shall be enforceable by, the Company's successors and
assigns.

          7.8   REFORMATION BY COURT. In the event that a court of competent
jurisdiction shall determine that any provision of this Article 7 is invalid or
more restrictive than permitted under the governing law of such jurisdiction,
then only as to enforcement of this Article 7 within the jurisdiction of such
court, such provision shall be interpreted and enforced as if it provided for
the maximum restriction permitted under such governing law.

          7.9   EXTENSION OF TIME. If the Executive shall be in violation of any
provision of this Article 7, then each time limitation set forth in this Article
7 shall be extended for a period of time equal to the period of time during
which such violation or violations occur. If the Company seeks injunctive relief
from such violation in any court, then the covenants set forth in this Article 7
shall be extended for a period of time equal to the pendency of such proceeding
including all appeals by the Executive.

          7.10  SURVIVAL. The provisions of this Article 7 shall survive the
termination of this Agreement, as applicable.

     8.   INJUNCTION. It is recognized and hereby acknowledged by the parties
hereto that a breach by the Executive of any of the covenants contained in
Article 7 of this Agreement will cause irreparable harm and damage to the
Company, the monetary amount of which may be virtually impossible to ascertain.
As a result, the Executive recognizes and hereby acknowledges that the Company
shall be entitled to an injunction from any court of competent jurisdiction
enjoining and restraining any violation of any or all of the covenants contained
in Article 7 of this Agreement by the Executive or any of his affiliates,
associates, partners or agents, either directly or indirectly, and that such
right to injunction shall be cumulative and in addition to whatever other
remedies the Company may possess.

     9.   ARBITRATION. Any dispute or controversy arising under or in connection
with this Agreement shall be settled exclusively by arbitration in Palm Beach
County, Florida, in accordance with the Rules of the American Arbitration
Association then in effect (except to the extent that the procedures outlined
below differ from such rules). Within thirty (30) days after written notice by
either party has been given that a dispute exists and that arbitration is
required, each party must select an arbitrator and those two arbitrators shall
promptly, but in no event later than thirty (30) days after their selection,
select a third arbitrator. The parties agree to act as expeditiously as
possible to select arbitrators and conclude the dispute. The selected
arbitrators must render their decision in writing. The cost and expenses of the
arbitration and of enforcement of any award in any court shall be borne by the
non-prevailing party. If advances are

                                     - 12 -
<Page>

required, each party will advance one-half of the estimated fees and expenses of
the arbitrators. Judgment may be entered on the arbitrators' award in any court
having jurisdiction. Although arbitration is contemplated to resolve disputes
hereunder, either party may proceed to court to obtain an injunction to protect
its rights hereunder, the parties agreeing that either could suffer irreparable
harm by reason of any breach of this Agreement. Pursuit of an injunction shall
not impair arbitration on all remaining issues.

     10.  SECTION 162(m) LIMITS. Notwithstanding any other provision of this
Agreement to the contrary, if and to the extent that any remuneration payable by
the Company to the Executive for any year would exceed the maximum amount of
remuneration that the Company may deduct for that year under Section 162(m)
("SECTION 162(m)") of the Code, payment of the portion of the remuneration for
that year that would not be so deductible under Section 162(m) shall, in the
sole discretion of the Board, be deferred and become payable at such time or
times as the Board determines that it first would be deductible by the Company
under Section 162(m), with interest at the "short-term applicable rate" as such
term is defined in Section 1274(d) of the Code. The limitation set forth under
this Section 10 shall not apply with respect to any amounts payable to the
Executive pursuant to Article 6 hereof.

     11.  ASSIGNMENT. Neither party shall have the right to assign or delegate
his rights or obligations hereunder, or any portion thereof, to any other
person.

     12.  GOVERNING LAW. This Agreement shall be governed by and construed and
enforced in accordance with the laws of the State of Florida, without reference
to principles of conflict of laws.

     13.  ENTIRE AGREEMENT; PRIOR AGREEMENTS. This Agreement constitutes the
entire agreement between the parties hereto with respect to the subject matter
hereof and, upon its effectiveness, shall supersede all prior agreements,
understandings and arrangements, both oral and written, between the Executive
and the Company (or any of its affiliates) with respect to such subject matter.
In addition, his shall supercede and replace the Executive's Prior Employment
Agreement, the Retention Agreement, as well as any and all other agreements
between the Executive and the Company and, upon execution of this Agreement by
the Executive and the Company, the Prior Employment Agreement, the Retention
Agreement and any and all other agreements between the Executive and the Company
shall terminate and shall no longer have any force and effect. Notwithstanding
this Article 13 or any other provision of this Agreement, Option Agreements
entered into by the Executive and the Company prior to the date of this
Agreement shall remain in full force and effect. This Agreement may not be
modified in any way unless by a written instrument signed by both the Company
and the Executive.

     14.  NOTICES: All notices and other communications hereunder shall be in
writing and shall be given by hand delivery to the other party or by registered
or certified mail, return receipt requested, postage prepaid, addressed as
follows:

                                     - 13 -
<Page>

          IF TO THE EXECUTIVE:

          Gregory A. Marsh
          10886 Magnolia Street
          Palm Beach Gardens, FL 33418

          IF TO THE COMPANY:

          AmeriPath, Inc.
          7289 Garden Road, Suite 200
          Riviera Beach, FL 33404
          Attention: Chairman of the Board

or to such other address as either party shall have furnished to the other in
writing in accordance herewith. Notice and communications shall be effective
when actually received by the addressee.

     15.  BENEFITS; BINDING EFFECT. This Agreement shall be for the benefit of
and binding upon the parties hereto and their respective heirs, personal
representatives, legal representatives, successors and, where permitted and
applicable, assigns, including, without limitation, any successor to the
Company, whether by merger, consolidation, sale of stock, sale of assets or
otherwise.

     16.  SEVERABILITY. The invalidity of any one or more of the words, phrases,
sentences, clauses, provisions, sections or articles contained in this Agreement
shall not affect the enforceability of the remaining portions of this Agreement
or any part thereof, all of which are inserted conditionally on their being
valid in law, and, in the event that any one or more of the words, phrases,
sentences, clauses, provisions, sections or articles contained in this Agreement
shall be declared invalid, this Agreement shall be construed as if such invalid
word or words, phrase or phrases, sentence or sentences, clause or clauses,
provisions or provisions, section or sections or article or articles had not
been inserted. If such invalidity is caused by length of time or size of area,
or both, the otherwise invalid provision will be considered to be reduced to a
period or area which would cure such invalidity.

     17.  WAIVERS. The waiver by either party hereto of a breach or violation of
any term or provision of this Agreement shall not operate nor be construed as a
waiver of any subsequent breach or violation.

     18.  DAMAGES. Nothing contained herein shall be construed to prevent the
Company or the Executive from seeking and recovering from the other damages
sustained by either or both of them as a result of its or his breach of any term
or provision of this Agreement. In the event that either party hereto brings
suit for the collection of any damages resulting from, or the injunction of any
action constituting, a breach of any of the terms or provisions of this
Agreement, then the party found to be at fault shall pay all reasonable court
costs and attorneys' fees of the other.

                                     - 14 -
<Page>

     19.  SECTION HEADINGS. The article, section and paragraph headings
contained in this Agreement are for reference purposes only and shall not affect
in any way the meaning or interpretation of this Agreement.

     20.  NO THIRD PARTY BENEFICIARY. Nothing expressed or implied in this
Agreement is intended, or shall be construed, to confer upon or give any person
other than the Company, the parties hereto and their respective heirs, personal
representatives, legal representatives, successors and permitted assigns, any
rights or remedies under or by reason of this Agreement.

     21.  WITHHOLDING TAXES. The Company may withhold from any amounts payable
under this Agreement such Federal, state or local taxes as shall be required to
be withheld pursuant to any applicable law or regulation.

     22.  COUNTERPARTS. This Agreement may be executed in one or more
counterparts, each of which shall be deemed to be an original but all of which
together shall constitute one and the same instrument and agreement.

     IN WITNESS WHEREOF, the undersigned have executed this Agreement as of the
date first above written.

EXECUTIVE:                              COMPANY:

                                        AMERIPATH, INC.

/s/ Gregory A. Marsh                    By: /s/ James C. New
---------------------------                 ----------------------------------
Gregory A. Marsh                            James C. New
                                            Chairman and Chief Executive Officer

                                     - 15 -
<Page>

                                    AMENDMENT
                             TO EMPLOYMENT AGREEMENT

          THIS AMENDMENT TO EMPLOYMENT AGREEMENT ("AMENDMENT") is made this 8
day of December 2002, by and between AMERIPATH, INC., a Delaware corporation
(the "COMPANY") and GREGORY A. MARSH (the "EXECUTIVE").

          WHEREAS, the Executive is currently employed by the Company pursuant
to an Employment Agreement dated April 9, 2001 (the "AGREEMENT");

          WHEREAS, the Company, Amy Holding Company (the "PARENT"), and Amy
Acquisition Corp. have entered into an Agreement and Plan of Merger, dated on or
about December 8, 2002 (the "MERGER AGREEMENT"); and

          WHEREAS, in connection with the Merger Agreement, the Company and the
Executive wish to amend the Agreement.

          NOW, THEREFORE, in consideration of the Executive's continued
employment with the Company and other good and valuable consideration, the
receipt and sufficiency of which is hereby acknowledged, the Company and the
Executive agree as follows:

          1.    EFFECTIVE DATE. This Amendment shall become effective on the
closing date of the transactions contemplated by the Merger Agreement (the
"EFFECTIVE DATE").

          2.    STOCK OPTIONS. On the Effective Date, the Executive will be
granted options to purchase at a $1 per share exercise price that number of
shares of common stock of the Parent equal to 1.00% of the Parent's common stock
outstanding on a fully-diluted basis as of the Effective Date, half of which
shall be granted in the form of a time-based option pursuant to an Time-Based
Option Agreement substantially in the form of EXHIBIT A hereto and half of which
shall be granted in the form of a performance-based option pursuant to a
Performance-Based Stock Option Agreement substantially in the form of EXHIBIT B
hereto (it being understood that (i) such 1.00% amount has been determined
assuming that, on the Effective Date, Welsh, Carson, Anderson & Stowe IX, L.P.
and its affiliated investors (collectively, "WCAS") will provide the equity and
debt financing contemplated in the financing commitment letters for the
transactions contemplated by the Merger Agreement and (ii) if WCAS is required
to provide additional equity financing to Parent in order to consummate the
transactions contemplated by the Merger Agreement, the equity issued to WCAS in
connection with such additional financing will dilute such 1.00% amount on the
same basis as other holders of Parent common equity securities).

<Page>

          3.    AMENDMENTS.

          (a)   The salary set forth in Section 4.1 of the Agreement is changed
to $240,000.

          (b)   Section 5.3 is deleted in its entirety.

          (c)   The second sentence of Section 6.1 is deleted in its entirety
and replaced with the following:

                For purposes of this Agreement, the term "for Cause" shall mean
     (i) an action or omission of the Executive which constitutes a willful and
     material breach of, or willful and material failure or refusal (other than
     by reason of his disability or incapacity) to perform his duties under,
     this Agreement or as reasonably directed by the Board of Directors of the
     Company or his superiors, in each case which, if curable, is not cured
     within fifteen (15) days after receipt by the Executive of written notice
     of same, (ii) fraud, embezzlement, misappropriation of funds or breach of
     trust or material violation of the Company's code of ethics in connection
     with Executive's services hereunder or with respect to the Company, (iii) a
     conviction or indictment of the Executive for, or the entering into a plea
     of nolo contendere by the Executive with respect to, a felony or any crime
     which involves dishonesty, fraud, embezzlement, misappropriation of funds
     or breach of trust, or (iv) gross negligence, reckless or willful
     misconduct by the Executive in connection with the performance of the
     Executive's duties hereunder, which the Board of Directors of the Company
     in its reasonable discretion deems to be good and sufficient cause to
     terminate the Executive's employment with the Company.

          (d)   Section 6.6 of the Agreement is deleted in its entirety and
replaced with the following:

     6.6  CHANGE IN CONTROL.

                a. Unless otherwise provided in Section 6.7 hereof, in the event
     that (i) a Change in Control (as defined in paragraph (d) of this Section
     6.6) shall occur during the Term of Employment or (ii) prior to the date on
     which a Change of Control occurs, the Term of Employment is terminated by
     the Company without Cause pursuant to Section 6.4 hereof or by the
     Executive as a result of the occurrence of a Diminution Event (as defined
     in paragraph (e) of this Section 6.6) and it is reasonably demonstrated
     that such termination or Diminution Event (A) was at the request of a third
     party who has taken steps reasonably calculated to effect a Change of
     Control, or (B) otherwise arose in connection with or anticipation of a
     Change of Control, the Company shall pay to the Executive, within thirty
     (30) days of the date of such Change in Control, a lump sum bonus equal to
     one and one half times the Executive's annual Base Salary.

                b. If, prior to the one-year anniversary of the closing of the
     transactions contemplated by that certain Agreement and Plan of Merger,
     dated on or about December 8, 2002, among AmeriPath, Inc., Amy Holding
     Company, and Amy Acquisition Corp.,

<Page>

     (i) the Term of Employment is terminated by the Company without Cause
     pursuant to Section 6.4 hereof or (ii) a Diminution Event occurs and the
     Executive elects to terminate the Term of Employment as a result thereof, a
     "Change of Control Termination" shall be deemed to have occurred.

                c. In the event of a "Change of Control Termination" under
     paragraph (b) of this Section 6.6, the Company shall: (i) pay to the
     Executive any accrued and unpaid Base Salary and Bonus Payment, through the
     effective date of the termination; (ii) pay to the Executive his
     Termination Year Bonus, if any, at the time provided in Section 4.2(b)
     hereof; (iii) pay to the Executive, within 30 days of the termination of
     his employment hereunder, a lump sum payment equal to one and one half
     times the Executive's annual Base Salary; and (iv) pay to the Executive in
     a lump sum the compensation and benefits provided in the Termination
     Without Cause Section 6.4.

                The Company shall have no further liability hereunder (other
     than for reimbursement for reasonable business expenses incurred prior to
     the date of termination, subject, however, to the provisions of Section
     5.1, and payment of compensation for accrued and unused vacation days).

                d. For purposes of this Agreement, the term "Change in Control"
     shall have the meaning ascribed to such term in the Executive's Time-Based
     Stock Option Agreement with AmeriPath Holdings, Inc.

                e. "Diminution Event" means either (i) the Company requires the
     Executive to be based at any office or location more than twenty-five (25)
     miles from that in which the Executive was based at the time this Amendment
     was executed (except for travel reasonably required in the performance of
     the Executive's duties and responsibilities under the Agreement) or (ii)
     the Executive's position (including status, offices, titles and reporting
     requirements), authority, duties and responsibilities are not at least
     commensurate in all material respects with the most significant of those
     held, exercised and assigned at the time preceding the date of this
     Amendment.

          (c)   The termination without Cause benefit, as set forth in
Section 6.4 is changed to eighteen (18) months of Executive's Base Salary, at
the time of termination, plus bonus (as defined in Section 4.2), eighteen (18)
months of COBRA premiums and an eighteen (18) month payout period.

          (f)   The non-compete provision, set forth in Section 7.1 is changed
to eighteen (18) months following the termination of the Executive's employment.

          4.    ACKNOWLEDGEMENT. The Company shall use its best efforts to cause
its own shareholders and the shareholders of the Parent, as applicable,
immediately prior to a Change of Control (as defined in the Executive's
Time-Based Stock Option Agreement with AmeriPath Holdings, Inc.) to approve any
payment or benefit (the "PAYMENT") that the Company and/or the Parent is
required to make to the Executive upon or in connection with the occurrence of a
Change of Control of the Company or the Parent in a manner that satisfies
Section

<Page>

280G(b)(5)(B) of the Internal Revenue Code of 1986, as amended, and the
regulations promulgated thereunder.

          5.    CONFLICTING TERMS AND SURVIVAL OF AGREEMENT. Except as
specifically set forth herein, the Agreement shall remain in full force and
effect. In the event the terms of this Amendment shall conflict with the terms
of the Agreement, the terms of this Amendment shall control.

          6.    COUNTERPARTS. This Amendment may be executed in any number of
counterparts, each of which shall be deemed to be an original, and all of which
together constitute one document.

          7.    FINAL AGREEMENT. The Agreement, as amended by this Amendment,
constitutes the final agreement between the parties hereto and supercedes any
prior or representation, oral or written, among them with respect to the matters
set forth in the Agreement and this Amendment.

                  [Remainder of Page Intentionally Left Blank]

<Page>

          IN WITNESS WHEREOF, the parties have executed this Amendment on the
date set forth above.

                                        AMERIPATH, INC.

                                        By: /s/ James C. New
                                            ------------------------------------
                                            James C. New
                                            Chairman and Chief Executive
                                            Officer

                                        EXECUTIVE:

                                        /s/ Gregory A. Marsh
                                        ------------------------------------
                                            Gregory A. Marsh

<Page>

                                 AMENDMENT NO. 2
                             TO EMPLOYMENT AGREEMENT

          THIS AMENDMENT NO. 2 TO EMPLOYMENT AGREEMENT is made this 26th day of
March 2003, by and between AMERIPATH, INC., a Delaware corporation (the
"COMPANY") and GREGORY A. MARSH (the "EXECUTIVE").

          WHEREAS, the Executive is currently employed by the Company pursuant
to an Employment Agreement, dated April 9, 2001, as amended December 8, 2002
(the "AGREEMENT");

          WHEREAS, the first amendment to the Agreement, dated December 8, 2002
("AMENDMENT NO. 1"), contemplated that the Executive would be granted options to
purchase capital stock of the Company at an exercise price of $1.00 per share
upon the closing date of the transactions contemplated by the Merger Agreement,
dated December 8, 2002 (the "MERGER AGREEMENT"), among the Company, Amy Holding
Company and Amy Acquisition Corp.;

          WHEREAS, the Executive and the Company have agreed that such options
will actually be issued at $6.00 upon the closing date of such transactions, and
as such, the Executive and the Company have agreed to further amend the
Agreement to reflect such revised exercise price;

          NOW THEREFORE, in consideration of the Executive's continued
employment with the Company and other good and valuable consideration, the
receipt and sufficiency of which is hereby acknowledged, the Company and the
Executive agree as follows:

          1.    EFFECTIVE DATE. This Amendment No. 2 shall become effective on
the closing date of the transactions contemplated by the Merger Agreement.

          2.    AMENDMENT. The reference to "$1 " as the exercise price of the
options to be granted the Executive pursuant to Section 2 of Amendment No. 1 is
hereby deleted and replaced with a reference to "$6" as the exercise price for
such options.

          3.    CONFLICTING TERMS AND SURVIVAL OF AGREEMENT. Except as
specifically set forth herein, the Agreement and Amendment No. 1 shall remain in
full force and effect. In the event the terms of this Amendment No. 2 shall
conflict with the terms of the Agreement and Amendment No. 1, the terms of this
Amendment No. 2 shall control.

          4.    COUNTERPARTS. This Amendment No. 2 may be executed in any number
of counterparts, each of which shall be deemed to be an original, and all of
which together constitute one document.

          5.    FINAL AGREEMENT. The Agreement, as amended by this Amendment
No. 2, constitutes the final agreement between the parties hereto and supercedes
any prior representation, oral or written, among them with respect to the
matters set forth in the Agreement, Amendment No. 1 and this Amendment No. 2.

<Page>

          6.    GOVERNING LAW. This Amendment No. 2 shall be governed by and
construed and enforced in accordance with the laws of the State of Florida,
without reference to principles of conflict of laws.

                  [Remainder of Page Intentionally Left Blank]

<Page>

          TN WITNESS WHEREOF, the parties have executed this Amendment on the
date set forth above.

                                        AMERIPATH, INC.

                                        By: /s/ James C. New
                                            ------------------------------------
                                            James C. New
                                            Chairman and Chief Executive Officer

                                        EXECUTIVE

                                        /s/ Gregory A. Marsh
                                        ----------------------------------------
                                        Gregory A. Marsh<Page>

                                                                   EXHIBIT 10.17

                              EMPLOYMENT AGREEMENT

     THIS AGREEMENT is made in duplicate, by and between ESSMAN LABORATORY
PHYSICIANS, JACKSONVILLE, P.A., hereafter called the "Employer," and
DENNIS M. SMITH, JR., M.D., hereafter called the "Employee."

     WHEREAS, Employee is duly licensed and otherwise legally authorized to
practice medicine; and

     WHEREAS, the Employer is a corporation duly authorized to engage in every
aspect of the practice of said profession and all its fields of specialization.

     NOW, THEREFORE, in consideration of the premises and of the promises herein
contained, the parties covenant and agree as follows:

     1.   RECITALS:

          The above recitals are true and correct and are made a part hereof.

     2.   EMPLOYMENT:

          The Employer agrees to employ the Employee from October 1, 1985 until
September 30, 1986 (such period being referred to hereafter as the "initial
term"), as a physician for the purpose of rendering, on behalf of the Employer,
professional medical services (including consulting and advice) to such members
of the general public as are, or hereafter shall be, accepted as patients by the
Employer. Unless otherwise terminated, such employment shall be extended from
year to year subsequent to the initial term. The initial term and any extension
thereof is hereafter referred to as the "period of active employment." This
Agreement may be terminated at the end of the initial term or at the end of any
extension thereof upon thirty (30) days' written notice prior to the end of such
period of active employment or as otherwise provided herein.

     3.   COMPENSATION:

          During the period of active employment, as defined above, the
Employer, in addition to incentive or bonus payments allocable to the Employee,
agrees to pay the Employee as compensation for the services of the Employee, as
follows:

          (a)  A basic annual salary of not less than $240,000.00 payable
pro rata at the end of each month for which services are rendered.

          (b)  Reimbursement for reasonable expenses actually incurred by the
Employee in the furtherance of the Employer's

<Page>

business, including, but not limited to, entertainment and attendance at
professional conferences, conventions and institutes, provided proper
itemization of said expenses is furnished the Employer by the Employee.

          (c)  Employer shall purchase on Employee's behalf medical insurance
coverage for employee, his spouse and his dependents. Employee shall have the
obligation to designate the policy to be purchased pursuant to this paragraph;
provided, however, that Employer shall have the right to decline to purchase the
selected policy, in which event, Employer shall select the policy to be
purchased for such purposes. In all events, the Employer shall have the right to
request that such policy provide for the maximum deductible amounts under the
policy provided by policies of designated insurors.

          (d)  Reimbursement for expenses related to medical diagnostic
procedures, including, but not limited to, routine medical examinations, blood
tests, x-rays, routine dental examinations, including x-rays, eye tests and
routine optical visits, and cost of travel for same at the rate of 20 cents per
mile. No reimbursement shall be made under this subparagraph for sums paid for
by medical insurance.

          (e)  Aggregate bonuses, director's fees (if applicable), management
committee fees and S corporation distributions comparable to the aggregate
bonuses, director's fees, management committee fees and S corporation
distributions provided to persons similarly situated payable on or about the end
of each term of this Agreement, the aggregate of such bonuses, director's fees,
management committee fees and S corporation distributions not to exceed, as to
any one fiscal year, $50,000; provided, however, that if this Agreement is still
in effect for the fiscal year beginning October 1, 1988, the aggregate shall not
exceed $100,000 for the fiscal year beginning October 1, 1988. Notwithstanding
the foregoing, there shall be no limitation on the amount of such bonuses,
director's fees, management committee fees and S corporation distributions for
each one year term of this Agreement during which the Employee is employed by
the Employer occurring after September 30, 1989, but only if, on or before June
30, 1990, the Employee has exercised all of his options to purchase the common
stock of Essman, Davis, Songster Laboratory Physicians, P.A. and Essman
Laboratory Physicians, Jacksonville, P.A. pursuant to the Stock Purchase
Agreement dated as of September 30, 1986 by and among Richard A. Essman, M.D.,
Larry J. Davis M.D., Curtis L. Songster, M.D., and Dennis Smith, M.D. For
purposes of this provision, the aggregate bonuses, director's fees, management
committee fees and S corporation distributions paid by Essman, Davis, Songster
Laboratory Physicians, P.A. and Essman Laboratory Physicians, Jacksonville, P.A.
to their senior physician employees shall conclusively be deemed comparable to
the aggregate bonuses, director's fees, management committee fees and S
corporation distributions provided to persons similarly situated.

                                       2.
<Page>

     4.   VACATION:

          The Employee shall be entitled to vacations with pay in accordance
with the vacation policy of the Employer promulgated from time to time by the
Employer.

     5.   WORKING FACILITIES:

          (a)  The Employee shall be furnished with an office, stenographic
help, and such other facilities and services as are suitable to his position and
adequate for the performance of his duties hereunder.

          (b)  Employee is required to maintain a telephone in his home for use
in his work. Employer agrees to reimburse Employee for the expense of
maintaining such telephone.

          (c)  Employee is required to furnish his own automobile for use in his
work. Employer shall reimburse Employee for that portion of use of such
automobile as is allocable to Employer's business.

          (d)  The Employer shall also furnish professional liability insurance
in such amounts as Employer from time to time determines to be appropriate.

     6.   FEES AND PATIENTS:

          (a)  All fees, compensation, monies and other things of value received
or realized as a result of the rendition of professional medical services by
the Employee shall belong to or be paid and delivered to the Employer.

          (b)  All patients treated by Employee are patients of the Employer and
shall be dealt with by Employee for and on behalf of Employer.

          (c)  The Employer shall have the exclusive authority to fix, and to
determine for fixing, fees to be charged to patients. The Employer shall have
the exclusive authority to determine who will be accepted as patients and the
exclusive authority for designating which professional employee of Employer will
serve each patient as well as the professional policies and procedures to be
followed by the Employee.

     7.   DUTIES:

          The Employee accepts employment with the Employer on the terms and
conditions herein set forth and agrees that during the period of active
employment, as defined above, he will devote his full business time and
attention to the rendition of professional medical services on 'behalf of the
Employer and to the furtherance of the Employer's best interests. The Employee
agrees that in the rendition of such professional medical services and

                                       3.
<Page>

in all aspects of his employment, he will comply with such reasonable policies,
standards and regulations of the Employer as are from time to time established,
and will carry out any duties as a physician to the best of his professional
ability. The Employee agrees to fully carry out any duties that the Employer may
give him, provided that such duties are not in conflict with applicable
standards of medical practice in Jacksonville, Florida. The Employee agrees
that, if requested so to do, he will serve as an officer and as a director of
the Employer without further pay.

     8.   EXTENT OF SERVICES:

          During the period of active employment, as defined above, the Employee
shall not undertake any professional medical business except for the benefit of
the Employer, unless the Employer shall consent thereto. The Employee may engage
in other business activities that do not conflict herewith which are approved by
the Employer.

     9.   FAILURE TO FURNISH INSURANCE BENEFITS:

          In the event of a failure of Employer to pay any insurance premiums or
provide any insurance coverage provided for by this Agreement or otherwise,
including but not limited to health, disability, casualty or liability insurance
of any kind or nature, Employer's liability shall be limited to the amount of
the premiums paid or to be paid for such insurance and in no event shall
Employer be held liable for any further or greater damage for the failure to
provide' neglect, such insurance, whether the same be the result of Employer's
neglect, default, or otherwise, or the default, neglect, or failure to provide
coverage by any other person.

     10.  AUTOMATIC TERMINATION FOR CAUSE:

          If the Employee for any reason ceases to be an active member of the
medical profession in good standing and duly licensed or otherwise legally
authorized within the State of Florida to render the same professional service
as the Employer, then, in any such event, all employment and relationship of the
Employee with the Employer shall automatically and immediately stand completely
severed and terminated.

     11.  EMPLOYER'S DETERMINATION OF TERMINATION FOR CAUSE:

          In addition to termination hereof as provided by paragraphs 10 and 13
hereof, this agreement may be terminated by the Employer at any time upon the
occurrence of one or more of the following events:

          (a)  In the event the Employee shall fail or refuse to comply with the
policies, standards and regulations of the Employer from time to time
established and such failure or refusal shall not have been cured within thirty
(30) days

                                       4.
<Page>

after the Employer notifies the Employee in writing of such failure or refusal;
or

          (b)  In the event the Employee shall be guilty of fraud, dishonesty or
other acts of misconduct in the rendering of professional medical services on
behalf of the Employer; or

          (c)  In the event the Employee shall fail or refuse to faithfully or
diligently perform the provisions of this agreement or the usual and customary
duties of his employment and such failure or refusal shall not have been cured
within thirty (30) days after the Employer notifies the Employee in writing such
failure or refusal; or

          (d)  In the event of a bona fide determination by the Employer to sell
or reduce to cash substantially all of the assets of the Employer, or to
distribute the Employer's assets in liquidation, or to discontinue the practice
of medicine by the Employer; or

          (e)  In the event the Employee makes an assignment for the benefit of
creditors; or

          (f)  In the event the Employee files a voluntary petition in
bankruptcy or becomes the subject of an involuntary petition in bankruptcy.

     12.  DEATH AND DISABILITY:

          (a)  If the Employee dies during the term of this employment, the
Employer shall pay to the estate of the Employee the compensation which would
otherwise be payable to the Employee up to the end of the month in which his
death occurs. In addition, the Employer shall pay $5,000 within sixty (60) days
after the death of the Employee to the widow of the Employee, or, if he is not
then survived by his widow, to the Employee's surviving children, in equal
shares, or, if there are no such surviving children, to the estate of the
Employee. Provided, however, the Employee may at any time and from time to time
change the designated beneficiary hereunder by a writing delivered to the
Employer and signed by the Employee.

          (b)  In the event the Employee is disabled because of accident or
sickness, his compensation, which would otherwise be payable, shall be paid
until the end of the month in which disability occurs. Thereafter, there shall
be no further obligation to pay the Employee under this Agreement.

     13.  EMPLOYMENT BY COMPETITORS:

          (a)  Notwithstanding anything in this Agreement to the contrary, if
during the initial term or thereafter, this Employment Agreement terminates or
if Employee's employment terminates under this Agreement, with or without cause,
voluntarily or

                                       5.
<Page>

involuntarily, by either party Employee agrees that for a period of two (2)
years after the termination of employment he shall not, within a radius of
twenty (20) miles from the then principal office of the Employer or within a
radius of the then principal office of Essman, Davis, Songster Laboratory
Physicians, P.A., own, manage, operate, control, be employed by, act as an agent
for, participate in or be connected in any manner with the ownership,
management, operation or control of any business which is engaged in the
practice of medicine or any of its subspecialties which are or may be
competitive to the business of the Employer or the business of Essman, Davis,
Songster Laboratory Physicians, P.A.

          (b)  It is the intention of the parties that the Employer be given the
broadest protection allowed by law with regard to the restrictions herein
contained. In the event of a breach or a threatened breach by the Employee of
provisions in this paragraph, the Employer shall be entitled to an injunction
restraining the Employee from such breach or threatened breach. Nothing herein
shall be construed as prohibiting the Employer from pursuing any other remedies
available to it for such breach or threatened breach including the recovery of
damages from the Employee. This covenant on the part of the Employer and
Employee shall be construed as an agreement independent of any other provision
of this Agreement and the existence of any claim or cause of action by the
Employee against the Employer whether predicated upon this Agreement or
otherwise shall not constitute a defense to the enforcement by the Employer of
this covenant. It is agreed by the Employer and the Employee that if any portion
of the covenant set forth in this paragraph 13 are held to be invalid,
unreasonable, arbitrary, or against public policy, then such portion of such
covenant shall be considered divisible both as to time and geographical area.
The Employer and the Employee agree that, if any court of competent jurisdiction
determines the specified time period or the specified geographical area
applicable to this paragraph 13 to be invalid, unreasonable, arbitrary or
against public policy, a lesser time period or geographical area which is
determined to be reasonable, nonarbitrary and not against public policy may be
enforced against the Employee. The Employer and Employee agree that the
foregoing covenants are appropriate and reasonable when considered in light of
the nature and extent of the business conducted by the Employer.

     14.  AGENCY:

          The Employee shall have no authority to enter into any contracts
binding upon the Employer, or to create any obligations on the part of the
Employer, except such as shall be specifically authorized by the Employer.

     15.  NOTICES:

          Any notice required or permitted to be given under this Agreement
shall be sufficient if in writing, and if sent by

                                       6.
<Page>

registered mail to his residence in the case of the Employee, or to the
principal office in the case of the Employer.

     16.  ARBITRATION:

          Any controversy or claim arising out of, or relating to this
Agreement, or the breach thereof, shall be settled by arbitration in the City
of St. Petersburg, Florida, in accordance with the Rules then obtaining by the
American Arbitration Association, and judgment upon the award rendered may be
entered in any court having jurisdiction thereof. This paragraph does not apply
to paragraph 13, EMPLOYMENT BY COMPETITORS.

     17.  BYLAWS, MISCELLANEOUS:

          (a)  This Agreement is made subject to and with reference to the
Bylaws of the Employer, which the Employee accepts as binding upon him and which
are adopted as part of the terms of this Agreement.

          (b)  To the extent legally and ethically possible, in the event the
Employee's name is now or hereafter used as part of the Employer's name, the
Employer may continue such use after the termination of employment of Employee.

     19.  ENTIRE AGREEMENT:

          This instrument contains the entire agreement of the parties. It may
not be changed orally but only by an agreement in writing signed by the party
against whom enforcement of any waiver, change, modification, extension or
discharge is sought. This Agreement replaces any prior employment agreement
between the parties.

     IN WITNESS WHEREOF, the parties hereto have executed this Agreement as of
the 1st day of October, 1985.

WITNESSES:

/s/ [ILLEGIBLE]                            /s/ Dennis M. Smith, Jr., M.D.
-----------------------------           ---------------------------------(SEAL)
                                        DENNIS M. SMITH, JR., M.D.

/s/ [ILLEGIBLE]                                    "EMPLOYEE"
-----------------------------

                                        ESSMAN LABORATORY PHYSICIANS,
                                          JACKSONVILLE, P.A.

/s/ [ILLEGIBLE]                         By:  /s/ [ILLEGIBLE]              (SEAL)
-----------------------------               ------------------------------
                                             President

/s/ [ILLEGIBLE]                                    "EMPLOYER"
-----------------------------

                                       7.
<Page>

                                 FIRST AMENDMENT

                                       TO

                              EMPLOYMENT AGREEMENT

     THIS FIRST AMENDMENT TO EMPLOYMENT AGREEMENT is made and entered into this
15th day of June, 1995, but is effective for all purposes as of October 1, 1994,
by and between ESSMAN, LABORATORY PHYSICIANS, JACKSONVILLE, P.A. a Florida
professional association (the "Employer"), and DENNIS M. SMITH, M.D. (the
"Employee").

                              W I T N E S S E T H:

     WHEREAS, on October 1, 1985, the Employee entered into an employment
agreement with the Employer (the "Agreement"); and

     WHEREAS, both the Employee and the Employer desire to amend the Agreement
in certain respects.

     NOW, THEREFORE, in consideration of the premises and the terms and
conditions hereof, the parties hereby agree to amend the agreement as follows:

     1.   Section 12(b) of the Agreement is hereby deleted and the following
substituted therefor:

          (b)  During any period of disability, illness or incapacity during the
     term of this Agreement which renders the Employee at least temporarily
     unable to perform the services required under this Agreement for a period
     which shall not equal or exceed ninety (90) days, the Employee shall
     continue to receive his basic salary, less any benefits received by him
     under any disability insurance carried by or provided by the Employer.
     Thereafter, there shall be no further obligation to pay the Employee under
     this Agreement. Successive periods of disability, illness or incapacity
     will be considered separate periods unless the later period of disability,
     illness or incapacity is due to the same or related cause and commences
     less than six months from the ending of the previous period of disability.

     2.   In all other respects, the Agreement shall remain in full force and
effect and as it was prior to this amendment and is hereby ratified and
affirmed.

<Page>

     IN WITNESS WHEREOF, the parties hereto have executed this First Amendment
to Employment Agreement the day and year first above written.

WITNESSES:                                ESSMAW LABORATORY PHYSICIANS,
                                          JACKSONVILLE, P.A.

/s/ [ILLEGIBLE]
-----------------------------

/s/ [ILLEGIBLE]                           By: /s/ [ILLEGIBLE]
-----------------------------                -----------------------------------
                                              President

                                                        EMPLOYER

/s/ [ILLEGIBLE]
-----------------------------

                                           /s/ Dennis M. Smith
                                          --------------------------------------
                                          DENNIS M. SMITH, M.D.
/s/ [ILLEGIBLE]
-----------------------------

                                                        EMPLOYEE

                                        2
<Page>

                             AMERIPATH FLORIDA, INC.

                              EMPLOYMENT AGREEMENT

     EMPLOYMENT AGREEMENT (the "Agreement") dated and effective as of December
1, 1997, by and between AMERIPATH FLORIDA, INC., a Florida corporation (the
"Company") and DENNIS M. SMITH, JR., M.D. (the "Employee").

     WHEREAS, prior to the date hereof, the Employee served as an employee of
and rendered professional services, as a Doctor of Medicine specializing in
Pathology, to Laboratory Physicians, Jacksonville, P.A. ("ELAB") providing
pathology services. Pursuant to a certain Stock Purchase Agreement (the
"Purchase Agreement") dated and effective as of December 1, 1997, which is an
otherwise validly enforceable agreement by and among AmeriPath, Inc., a Delaware
corporation ("AmeriPath"), ELAB and the Shareholders of ELAB, including the
Employee, all of the capital stock of ELAB has been purchased by and sold,
transferred and conveyed to AmeriPath and the Company (the "Acquisition"),
effective the date hereof (ELAB's business segment shall be referred to herein
as the "Jacksonville Division" of the Company).

     WHEREAS, accordingly, and in connection with the transactions and
agreements referred to above, the Employee has agreed to terminate his
employment with ELAB and to become employed by and render professional services
to the Company as the Managing Director of the Jacksonville Division and as a
Doctor of Medicine specializing in Pathology, and the Company has agreed to
engage the Employee to render such services on the Company's behalf, in each
case on the terms and subject to the conditions set forth herein.

     NOW, THEREFORE, for and in consideration of the foregoing premises and the
mutual covenants and agreements contained herein, and for other good and
valuable consideration, the receipt and sufficiency of which are hereby
acknowledged, the Employee and the Company, intending to be legally bound,
hereby agree as follows:

     1.   EMPLOYMENT. Subject to the terms and conditions of this Agreement, the
Company shall employ the Employee to render professional services to the Company
as the Managing Director of the Jacksonville Division and as a Doctor of
Medicine specializing in Pathology, and the Employee accepts such employment and
such position. The Employee has terminated his employment with ELAB.

     2.   TERM. The Company shall employ the Employee for a period commencing
the date hereof and ending on November 30, 2002, subject to termination prior to
such date pursuant to Section 15 or 17 hereof. At the end of such five (5) year
period, this Agreement will automatically continue in effect for additional one
(1) year terms, on terms no less favorable to the Employee than those contained
herein, unless either party hereto gives written notice to the other party at
least sixty (60) days prior to the end of such term (or any extension thereof)
of such party's determination to terminate this Agreement. If such notice is
given, then the Employee's employment will terminate at the end of such term (or
on such other date as the parties mutually agree). If such notice is not given,
then the Employee's employment will continue hereunder for

<Page>

an additional year, subject to termination prior to such date pursuant to
Section 15 or 17 hereof. The parties agree to begin negotiating the terms of
each renewal hereunder no less than six (6) months in advance of the expiration
of the current term.

     3.   DUTIES AND PERFORMANCE. The Employee agrees to devote the Employee's
best efforts and full professional time to providing services in the practice of
medicine on the Company's behalf, and the Employee shall maintain the Company's
standards and professional ethics and those of the medical profession. In
addition to rendering professional services as the Company's employee and
Managing Director of the Jacksonville Division, the Employee is also expected as
part of the Employee's duties as the Company's employee to engage in marketing
activities designed to promote the Company's practice, as well as administrative
and compliance activities, all as directed by the Board of Directors of the
Company. The Employee's marketing responsibilities shall be directed at
developing the Company's business in the Florida counties of ???val, St. John's,
Clay, Bradford, Union, Baker, Nassau and Putnam and the Georgia counties of
Camden, Brantley, Ware and Charlton (collectively these Florida and Georgia
counties referred to herein as the "Jacksonville Territory"). Except as may be
permitted in writing by the Company or otherwise provided herein, the Employee
is not to practice medicine other than with the Company during the term of this
Agreement (and thereafter, pursuant to Section 20 hereof), ???r is the Employee
to engage in any other gainful occupation without the Company's prior written
consent. Notwithstanding, the Employee may engage in the practice of medicine in
the course of the Employee's duties as a member of the U.S. Military, either
active or reserve, or the ??ational Guard. To the extent that such activities do
not interfere with the Employee's full time service to the Jacksonville Division
of AmeriPath, the Employee may also engage in the activities indicated in the
last sentence of Section 20(b)(2) hereof, engage in personal investment
activities (not otherwise in conflict with the terms of this Agreement),
including serving on the Board of Directors of Medical Equities Partners, and
participate in community activities. Additional duties of the Employee are set
forth below in this Agreement. NOTWITHSTANDING ANYTHING TO THE CONTRARY
CONTAINED HEREIN, NOTHING SHALL IMPAIR THE INDEPENDENT MEDICAL JUDGMENT OF THE
EMPLOYEE.

     4.   QUALIFICATIONS AND LICENSURE. The Employee shall at all times during
the term of this Agreement: (i) be certified by the American Board of Pathology
in anatomic pathology or the Board Eligible; (ii) maintain an unlimited and
unrestricted license to practice medicine in the State of Florida; (iii)
maintain appropriate medical staff membership and privileges at all medical
facilities presently served or serviced by the Employee, and use his best
efforts to gain and maintain appropriate medical staff membership and privileges
at any additional medical facilities identified by the Company; (iv) comply with
the Florida Board of Medicine and the Company's continuing medical education
("CME") requirements; (v) carry out the Employee's responsibilities on a
professional, ethical and diligent basis in order to serve the best interests of
the Company's patients, customers and clients; and (vi) comply with such other
requirements applicable to all of the Company's physician employees as the Board
of Directors of the Company may hereinafter reasonably impose, including without
limitation the Company's rules, regulations, policies and procedures (the "Rules
and Regulations") to the extent that such Rules

                                        2
<Page>

and Regulations are reasonable and do not conflict with the Employee's rights
provided by this agreement.

     5.   MEDICAL FACILITIES; LOCATION. The Employee will accept assignment for
duty in ?? reasonable location within the Jacksonville Territory in which the
Company renders ??hology services during the term of this Agreement and to
perform such duties as the Company ??y reasonably direct. In the event that
Employee is relocated, the Company shall pay employee's reasonable moving costs.

     6.   CONFORMITY WITH LAWS, RULES, REGULATIONS AND POLICIES. In performing
the employee's duties under this Agreement, the Employee shall comply with (i)
all applicable laws, rules and regulations, ordinances and standards of any
governmental, quasi-governmental or private authority having either mandatory or
voluntary jurisdiction over the Company, the employee, or any medical facility
for which the Employee provides services, (ii) the written ??laws, rules and
regulations, policies and procedures of any such medical facility, including,
without limitation, the residential boundary requirements of such hospitals or
medical facilities, and (iii) the Company's Rules and Regulations to the extent
that the foregoing are reasonable and do not conflict with the Employee's rights
provided by this Agreement.

     7.   SALARY; FRINGE BENEFITS. During the term of the Employee's employment
under ??s Agreement, in consideration for all services rendered for and on
behalf of the Company, the employee shall be entitled to receive a salary at the
annual rate of $250,000 payable in accordance with the Company's regular payroll
practices in effect from time to time. In addition to the Employee's salary, the
Employee will also be entitled to fringe benefits comparable to those which the
Company provides to other physician employees having tenure, experience,
specialities, responsibilities, educational background and other qualifications
similar to those of ??e Employee. The Employee's hours shall be reasonable and
comparable to other like physicians in similar positions within the Company.
Employee shall be eligible to receive an annual award of options to purchase
10,000 shares (to be appropriately adjusted for stock dividends, splits, etc.),
or such other amount as determined by the Board of Directors of AmeriPath, of
AmeriPath common stock, in accordance with the terms and provisions of
AmeriPath's Stock Option Plan. Such awards of stock options shall be based on
the achievement ?? certain EBIT targets referenced in the Purchase Agreement and
shall be subject to the discretion of AmeriPath's Board of Directors; however,
if AmeriPath's Board of Directors does approve the grant, Employee shall receive
his designated share of stock options.

     8.   REIMBURSEMENT OF EXPENSES.

          Upon submission of proper documentation and approval, the Company will
reimburse the Employee's reasonable expenses incurred in connection with the
Employee's employment by the Company, subject to compliance with reimbursement
policies from time to time adopted by the Company. Reimbursable expenses,
subject to prior approval, include:

               (a)  License fees and membership dues in professional
     organizations.

                                        3
<Page>

               (b)  The Employee's necessary travel, room, board and other
     expenses incurred in providing services at the Company's request or
     otherwise for the benefit of the Company.

               (c)  The Employee's business expenses if ordinary and necessary
     and in furtherance of the Company's business.

               (d)  Expenses with respect to CME and subscriptions to
professional and business journals and books.

               (e)  Promotional expenses of the type and nature as historically
made by the Jacksonville Division not to exceed $45,000 per calendar year.

     9.   MALPRACTICE INSURANCE.

          (a)  WHILE THE EMPLOYEE IS EMPLOYED BY THE COMPANY. The Company shall
maintain policies of professional liability insurance on the Employee (including
coverage for prior acts) and the Company's other employees in such amounts and
on such terms as the Company may determine; provided that such amounts of
coverage shall be equal to or greater than $ 1,000,000 per occurrence/
$5,000,000 in the aggregate per physician and the Company will maintain surplus
levels of coverage of $5,000,000 and $10,000,000 with limits in the aggregate of
$16,000,000 and $20,000,000. The Employee shall use all reasonable best efforts
to comply with any requirements or standards imposed on the Employee or the
Company by the terms of the insurance, and the Employee shall furnish such
information as the insurer or the Company shall require. The Company shall
advise the Employee of any changes with respect to the insurer or the insurance
coverages as set forth herein. The Employee may recommend counsel to handle
medical malpractice claims, subject to the prior written approval of the
insurer.

          (b)  TAIL COVERAGE.

               (1)  If the Employee's employment is terminated for cause (as
     defined in Section 15 hereof) or if the Employee terminates his employment
     with the Company for any reason, other than for the death or Disability
     (as defined in Section 17(b)) of the Employee, then, except as hereinafter
     provided, the Company shall have the option, but not the obligation, of
     purchasing malpractice insurance "tail" coverage, for the period of the
     applicable statute of limitations, to provide coverage for the Employee's
     professional acts prior to the date of termination. If the Company acquires
     this "tail" coverage, its reasonable cost shall be borne and paid by the
     Employee. If the Employee fails to provide and pay for such tail coverage,
     then the Company shall have the right to obtain such tail coverage and
     deduct and set-off its cost from payments otherwise payable to the
     Employee.

                                        4
<Page>

               (2)  If the Employee's employment terminates for any reason other
     than those set forth in (1) above, including, but not limited to, the
     Company's decision not to renew this Agreement, the Company, at its sole
     cost and expense, shall obtain "tail" coverage. Notwithstanding the
     foregoing, if, after termination of employment, the Employee continues in
     the practice of medicine and maintains malpractice insurance that includes
     coverage for the Employee's acts prior to termination of employment, then
     the Employee shall cause the Company to be a named insured as to those
     prior acts.

     10.  FEES; PAYMENTS. The Company has, and hereby reserves, the sole and
exclusive authority to determine the fees (or a procedure for establishing the
fees) to be charged to the Company's patients, customers and clients. Except as
otherwise contemplated herein, all fees for professional services rendered by
the Employee during the term of this Agreement shall be the Company's sole and
exclusive property (subject to the contract rights of certain third parties).
If, for any reason, any checks or other payments for such services due to the
Company are made payable to the Employee, the Employee will endorse and deliver
those checks or payments to the Company. The Employee also hereby authorizes the
Company to endorse and negotiate on the Employee's behalf any such checks or
payments. In addition, the Employee agrees, upon the Company's request, to
account to the Company for any such fees which may have been received by the
Employee.

     11.  ACCEPTANCE OF PATIENTS/REFERRALS OF BUSINESS. The Company shall have
the sole and exclusive authority to determine who will be accepted as patients
of the Company's practice and to designate, and establish a procedure for
designating, which professional employee of the Company will handle each such
patient. The Company will direct all new business clients and opportunities
within the Jacksonville Territory to the Jacksonville Division and all specimens
originating from the Jacksonville Territory (other than those accounts currently
handled by existing AmeriPath facilities within the Jacksonville Territory) will
be directed to the Jacksonville Division; provided, however, that if a client
requests that it be serviced by another division of AmeriPath, or if the
Jacksonville Division is unable to service the client, the client will be
referred to another division of AmeriPath.

     12.  PROFESSIONAL RULES AND REGULATIONS. The Company shall at all times
have the exclusive authority to establish reasonable professional policies and
procedures to be followed by the Employee in rendering professional services on
the Company's behalf, and the Employee agrees to follow the Rules and
Regulations established by the Company from time to time to the extent that such
Rules and Regulations are reasonable and do not conflict with the Employee's
rights provided by this Agreement. The Rules and Regulations shall, where
applicable and appropriate, be applied on a consistent basis to all of the
Company's physician employees.

     13.  MEDICAL RECORDS AS COMPANY PROPERTY. All medical records, charts, case
histories, x-rays, specimens, tissue samples and lab reports and analyses of or
concerning patients of the Company ("Medical Records") received by the Employee
shall be and remain the Company's property. During the term of this Agreement
and thereafter, the Employee will comply with all of the Company's Rules and
Regulations regarding confidentiality of the

                                        5
<Page>

Medical Records. The Employee shall have the right to copies of such Medical
Records that are necessary for defense of litigation or are required for
patients.

     14.  PAID VACATION AND TIME OFF. The Employee shall be entitled to a total
of four weeks of paid leave time per year (pro rated for any period of
employment of less than an ??e year), said leave time to include vacation time
and other time off and to exclude such time ?ay be taken by the Employee to
satisfy the Employee's applicable CME requirements, up to maximum of two (2)
weeks per year. All leave time must be coordinated to ensure adequate ??rage of
the Company's patients, customers and clients. All paid leave time must be taken
during the year in which it is earned and available, and thus will not be
carried forward or usable ??y subsequent year. No cash payments will be made by
the Company in respect of any ??ed but unused paid leave time.

     15.  TERMINATION OF AGREEMENT.

          (a)  TERMINATION FOR CAUSE. The Company may, in its sole and absolute
??etion, terminate the employment of the Employee hereunder, at any time prior
to the ??ration of the Employee's employment term(s) hereunder, immediately upon
written notice to Employee, or at such later time as the Company may specify in
such notice, if such ??ination is for "cause". As used in this Agreement, the
term "cause" means as follows:

               (1)  If the Employee is terminated or suspended for any period of
     time from Medicare, Medicaid or any state or federally funded program and
     such termination or suspension shall continue for a period of thirty (30)
     days after notice thereof by the Company;

               (2)  If the Employee's right to practice medicine in any state is
     suspended, restricted, revoked, lapsed (other than a lapse due to the
     Employee's voluntary failure to maintain such license after becoming a
     nonresident of that state);

               (3)  If the Employee (i) willfully damages the Company's
     property, business, reputation or goodwill (ii) steals from the Company,
     (iii) commits fraud or (iv) embezzles;

               (4)  If the Employee is convicted of a crime involving moral
     turpitude or any felony;

               (5)  If the Employee is continually inattentive to, or neglectful
     of, the duties to be performed by the Employee, which inattention or
     neglect is not the result of illness or injury, and such inattentiveness or
     neglectfulness shall continue for a period of thirty (30) days after
     written notice thereof by the Company;

               (6)  If, the Employee uses any mood altering or controlled
     substances except as prescribed by a physician, or if the Employee uses
     alcohol to excess;

                                        6
<Page>

               (7)  If the Employee willfully injures any independent
     contractor, employee, or agent of the Company, or willfully injures any
     person in the course of the performance of services for or on behalf of the
     Company;

               (8)  If the Employee's medical staff privileges or membership in
     any medical facility are suspended, restricted, revoked (other than a
     revocation occurring solely because the Employee has voluntarily ceased to
     perform medical services at such hospital with the Company's consent or
     such other restriction which does not materially impact the Employee's
     performance of his obligations under this Agreement), placed under
     probation, proctoring or observation and case review;

               (9)  If a guardian or conservator for the Employee is appointed
     by a court of competent jurisdiction;

               (10) If the Employee sexually harasses any employee or contractor
     of the Company or commits any act which otherwise creates an offensive work
     environment for employees or contractors of the Company and such conduct
     persists after receiving notice thereof from the Company.

               (11) The Employee's failure for any reasons to maintain the
     Employee's board certification in the medical specialty of Pathology
     provided that such failure has a material adverse impact on the Employee's
     ability to perform his duties under this Agreement;

               (12) If the Employee fails to comply with any of the terms or
     conditions of this Agreement and such failure to comply shall continue for
     a period of thirty (30) days after notice thereof by the Company.

               (13) If the Employee accepts other employment that places
     restrictions or limitations on the Employee's ability to continue rendering
     professional services under this Agreement;

               (14) The Company reasonably believes that the Employee has
     furnished deceptive or fraudulent information in the Employee's application
     for credentialing or recredentialing;

               (15) The Employee engages in criminal, unethical or fraudulent
     conduct or engages in conduct which adversely affects the Company, or the
     Employee is found guilty of such conduct by any entity or governmental
     agency of competent jurisdiction; provided, however, with respect to
     paragraphs (5) and (6) above, the Company shall have provided the Employee
     with written notice specifying the objectionable behavior, and, within
     thirty (30) days of receipt of the notice, the Employee shall have failed
     to cure such behavior or, in the sole judgment of the Company, as the case
     may be (as set forth above), failed to demonstrate reasonable progress
     towards curing such behavior.

                                        7
<Page>

     Where notice by the Company is required pursuant to a particular clause of
this Section ??(a), the Employee shall be given an opportunity to cure between
the date of receipt of such notice and the expiration of 30 days from such date.
The Company shall not be limited to termination as a remedy for any damaging,
injurious, improper or illegal act by the Employee, but may also seek damages,
injunction, or such other remedy as the Company may deem appropriate under the
circumstances. If the Employee's employment is terminated for cause, the Company
shall pay Employee his salary and benefits hereunder through the effective date
of termination of employment, and Employee agrees to vacate the Company's
offices on or before the effective date of the termination and to return and
deliver to the Company at such time all Company property.

          (b)  TERMINATION BY THE EMPLOYEE. Provided that the Company does not
have ??cause" to terminate the Employee pursuant to subsection "a" above, the
Employee may terminate the Employee's employment with the Company hereunder at
any time and for any reason; PROVIDED, HOWEVER, the Employee must provide to the
Company written notice of such determination not less than 120 days prior to the
date such termination is to be effective or as required by Section 2 hereof, and
the Employee shall be entitled to receive and be paid solely the Employee's
salary then in effect, through the effective date of such termination, payable
during such period at the Company's regular and customary intervals for the
payment of salaries as then ?? effect, and the Company shall have no further
obligation or liability to the Employee hereunder.

          (c)  TERMINATION BY THE COMPANY WITHOUT CAUSE. The Company may, in its
sole and absolute discretion, terminate the employment of the Employee
hereunder, at any time prior to the expiration of the Employee's employment
term(s) hereunder, without "cause" (as such term is defined in subsection (a)
above), or otherwise without any cause, reason or justification, provided that
the Company provides to the Employee at least sixty (60) days' prior written
notice (the "Termination Notice") of such termination. In the event of any such
determination by the Company, (i) the Employee's employment with the Company
shall cease and terminate on the date specified in the Termination Notice (or,
if no date is so specified, on the date which is 60 days following the date of
such notice), and (ii) the Employee shall be entitled to receive and be paid
solely the Employee's salary and other benefits then in effect, through the date
which is the later of (x) November 30, 2000, or (y) one year following the
termination date specified in the Termination Notice (or, if earlier, one year
following the date of such notice), payable during such year at the Company's
regular and customary intervals for the payment of salaries and benefits as then
in effect, and the Company shall have no further obligation or liability to the
Employee hereunder.

     16.  THE EMPLOYEE'S DUTIES UPON EXPIRATION OR TERMINATION. If this
Agreement expires or is otherwise terminated for any reason:

          (a)  Unless the Employee and the Company otherwise agree in writing,
the Employee will immediately resign from all (i) director, officer, fiduciary
and/or trustee positions held with the Company, and (ii) staff and similar
privileges at any medical facility for which the

                                        8
<Page>

Company has rendered medical services at any time during the two-year period
prior to the expiration or termination of this Agreement.

          (b)  The Employee will immediately return to the Company all books and
records of the Company in the Employee's possession, including, but not limited
to, books and records relating to pathology services rendered by the Employee
under this Agreement, Medical records, meeting minutes, board summaries and
financial reports or data.

     17.  TERMINATION OF EMPLOYMENT UPON DEATH OR DISABILITY.

          (a)  DEATH OF THE EMPLOYEE. In the event that the Employee shall die
during the term of his employment under this Agreement, the Employee's
employment with the Company shall immediately cease and terminate and the
Employee's estate, heirs (at law), advisees, legatees or other proper and
legally-entitled descendants, or the personal representative, executor,
administrator or other proper legal representative on behalf of such
descendants, shall be entitled to receive and be paid solely the Employee's
salary, then in effect, for a period of 60 days, payable at the Company's
regular and customary intervals for the payment of salaries as then in effect,
and the Company shall have no further obligation or liability under this
Agreement ??her than for any reimbursement of reasonable out-of-pocket business
expenses properly ???urred by the Employee prior to his death and documented to
the Company in accordance herewith). Any stock options of Employee that have
vested by their terms as of the date of Employee's death may be exercised by
Employee's estate in accordance with the terms of such ??tions.

          (b)  DISABILITY OF THE EMPLOYEE. In the event that the Employee
becomes ??acitated during the term of his employment hereunder by reason of
sickness, accident or ?? mental or physical disability such that he is
substantially unable to perform his duties and responsibilities hereunder for a
period of 60 consecutive days, or for shorter or intermittent periods
aggregating 90 days during any 12-month period (a "Disability"), the Company
hereafter shall have the right, in its sole and absolute discretion, to
terminate the Employee's employment under this Agreement by sending written
notice of such termination to the employee or his legal guardian or other proper
legal representative and thereupon his employment hereunder shall immediately
cease and terminate. In the event of any such termination, the Employee shall be
entitled to receive and be paid solely his salary, then in effect, ?? a period
of 60 days, payable at the Company's regular and customary intervals for the
payment of salaries as then in effect, less any amounts, payments or benefits
the Employee receives under the Company's disability insurance policy for such
time period, and the Company shall have no further obligation or liability under
this Agreement (other than for any reimbursement of reasonable out-of-pocket
business expenses properly incurred by Employee ??or to his Disability and
documented to the Company in accordance herewith). Any stock ??tions of Employee
that have vested by their terms as of the date of Employee's termination by
reason of Disability may be exercised by Employee or his guardian in accordance
with the terms of such options.

                                        9
<Page>

     18.  LIMITATIONS ON AUTHORITY. Unless the Company has given the Employee
its ??press written consent and except as otherwise in the ordinary course of
business, the Employee ??s absolutely no authority to:

          (a)  Pledge the credit or assets of the Company (or any Affiliate of
the Company) or of any of the Company's other employees.

          (b)  Bind the Company (or any Affiliate of the Company) under any
contract, agreement, note, mortgage or other instrument (other than routine
purchase orders in the ordinary course of business consistent with the Company's
practices).

          (c)  Release or discharge any debt due the Company (or any Affiliate
of the Company).

          (d)  Sell, mortgage, transfer or otherwise dispose of any of the
Company's assets (or any assets of any Affiliate of the Company).

     19.  REPRESENTATIONS OF EMPLOYEE. The Employee represents and warrants at
all times during the term of this Agreement that:

          (a)  The Employee is duly licensed and registered and in good standing
under the laws of the State of Florida to engage in the practice of medicine,
and that said license and registration have not been suspended, revoked or
restricted in any manner.

          (b)  The Employee is qualified for and has obtained, or has applied
for, membership in good standing on the medical staff of each hospital in which
such privileges are necessary for the Employee to render services.

          (c)  The Employee has and will continue to truthfully disclose to the
Company the following matters, whether occurring, at any time during the five
(5) years immediately preceding the date of this Agreement or at any time during
the term of this Agreement:

               (1)  any actual or threatened malpractice suit, claim (whether or
     not filed in court), settlement, settlement allocation, judgment, verdict
     or decree against the Employee;

               (2)  any disciplinary, peer review or professional review
     investigation, proceeding or action instituted against the Employee by any
     licensure board, hospital, medical school, health care facility or entity,
     professional society or association, third party payor, per review or
     professional review committee or body, or governmental agency;

               (3)  any criminal complaint, indictment or criminal proceeding in
     which the Employee is named as a defendant;

                                       10
<Page>

               (4)  any allegation, investigation, or proceeding, whether
     administrative, civil or criminal, against the Employee of filing false
     health care claims, violating anti-kickback laws, violating self-referral
     laws, violating fee splitting laws, or engaging in other billing
     improprieties;

               (5)  any organic or mental illness or condition that impairs or
     is likely to impair the Employee's ability to practice medicine;

               (6)  any dependency on, or habitual use or abuse of, alcohol or
     controlled substances, or any participation in any alcohol or controlled
     substance detoxification, treatment, recovery, rehabilitation, counseling,
     screening or monitoring program;

               (7)  any allegation, investigation or proceeding, whether
     administrative, civil, or criminal, against the Employee for violating
     professional ethics or standards, or engaging in illegal, immoral or other
     misconduct (of any nature or degree), relating to the practice of medicine;
     and

               (8)  any denial or withdrawal of an Employee's application in any
     state for licensure as a physician, for medical staff privileges at any
     hospital or other health care entity, for re-certification, for
     participation in any government third-party payment program, for state or
     federal controlled substances registration, or for malpractice insurance,
     or loss of board certification in the medical specialty of anatomic
     pathology or in the medical specialty of general pathology for any reason
     whatsoever.

          (d)  The Employee is board certified in the medical specialty of
pathology.

          (e)  The Employee shall at all times render services to patients in a
competent, professional and ethical manner, in accordance with prevailing
standards of medical practice in the relevant community, perform professional
and supervisory services in accordance with recognized standards of the medical
profession, and act in a manner consistent with the Principles of Medical
Ethics of the American Medical Association, American Board of Pathology and all
applicable statutes, regulations, rules, orders and directives of any and all
applicable governmental and regulatory bodies having competent jurisdiction.

          (f)  In connection with the provision of professional services to
patients of Company, the Employee shall use the equipment, instruments,
pharmaceuticals and supplies furnished by or on behalf of the Company for the
purposes for which they are intended and in a manner consistent with sound
medical practice.

          (g)  The Employee shall participate in Medicare, Medicaid, workers
compensation, other federal and state reimbursement programs, and the payment
plan of any commercial insurer, health maintenance organization, preferred
provider organization, accountable health plan, or other health benefit program,
as reasonably directed by the Company, and the Employee has not been suspended
or excluded from participating in any such program

                                       11
<Page>

which will have a material adverse impact on the ability of the Employee to
perform his duties as required by this Agreement.

          (h)  The Employee shall keep and maintain (or cause to be kept and
maintained) appropriate records, consistent with prevailing standards of medical
practice in the Employee's relevant community, relating to all professional
services rendered by the Employee under this Agreement and shall prepare and
attend to, in connection with such services, all reports, claims, and
correspondence necessary or appropriate in the circumstances, as determined
reasonably by the Company, all of which records, reports, claims, and
correspondence shall belong to the Company.

     20.  NON-COMPETITION AND NON-SOLICITATION AGREEMENT.

          (a)  The Employee acknowledges that during the course of the
Employee's employment the Employee has and will receive confidential and
proprietary information from and concerning the Company. The Employee also
acknowledges that the Company has made and/or will make substantial investments
in the further development of the Company's goodwill and in the Employee's
professional development. The capital expended to develop this goodwill directly
benefits the Employee and should continue to do so in the event that the
relationship between the Company and the Employee is terminated. Likewise, other
capital investments made or to be made by the Company to assist in the
Employee's professional development (including but not limited to those items
listed below) have conferred and will confer a direct economic benefit on the
Employee. During the course of the Employee's tenure with the Company, the
Employee will have received the following economic benefits as a result of
capital expenditures by the Company:

               (1)  Placement in an ongoing practice of pathology with an
     established revenue base.

               (2)  The opportunity to establish a professional relationship
     among clients served by the Company and its affiliates.

               (3)  Marketing support enabling the Employee to expand the
     Employee's own pathology practice and to become known by additional
     clients.

               (4)  The provision of contract management to enable the Employee
     to obtain provider status in managed care plans.

               (5)  The opportunity to develop special areas of expertise
     leading to requests for consultations on specific areas of pathology
     practice.

               (6)  The establishment of methodologies, practice parameters and
     quality assurance programs to enhance the Employee's practice of pathology.

                                       12
<Page>

               (7)  The development and implementation of information systems
     and reporting formats, unique to the practice of pathology, to make the
     provision of pathology services more efficient, and to maximize the time
     available to the Employee for the performance of pathology (as opposed to
     attending to administrative functions).

               (8)  Financial support and practice coverage to facilitate
     participation in continuing education opportunities.

               (9)  Financial support and practice coverage enabling the
     Employee to pursue additional board certifications.

               (10) Financial support and practice coverage to participate in
     professional development and professional associations.

               (11) Participation in proprietary strategic planning sessions
     which focus on professional and business aspects of the practice of
     pathology and growth opportunities.

     The Employee agrees that the Company is entitled to protect these business
interests and investments and to prevent the Employee from using or taking
advantage of the foregoing economic benefits to the Company's detriment.

          (b)  Accordingly, the Employee specifically agrees that, except for
the services and duties that the Employee performs for or on behalf of the
Company pursuant to the terms of this Agreement or other services that are
permitted pursuant to Section 20(b)(2) of this Agreement, during the Employee's
employment with the Company and during the Restricted Period (as defined in
Subsection (c) below), the Employee shall not, as a shareholder, principal,
agent, consultant, manager, advisor, director, officer, control person,
operator, or in any other capacity or manner whatsoever,

               (1)  directly or indirectly engage in the practice of pathology,
     or engage in any business or perform any service, directly or indirectly,
     in competition with the business of the Company, AmeriPath, the Company's
     or AmeriPath's successors and assigns in the Restricted Territory (as
     hereinafter defined), or have any interest whatsoever in any enterprise
     that shall so engage in such activities, which is located in, provides
     services in or does any business whatsoever (other than at a deminimis
     level) in any facility, hospital or laboratory located in the Florida
     counties of Pinellas, Hillsborough, Duval, St John's, Clay, Bradford,
     Union, Baker, Nassau and/or Putnam and the Georgia counties of Glynn,
     Camden, Brantley, Ware and Charlton (collectively these Florida and Georgia
     counties referred to herein as the "Restricted Territory"), or

               (2)  from any facility or location, whether within or without the
     Restricted Territory, knowingly (x) perform pathology services for any
     patient, medical facility, hospital, laboratory or health care provider
     located in the Restricted Territory or (y) perform pathology services for
     any patient, medical facility, hospital, laboratory or

                                       13
<Page>

     health care provider who was or is or is expected shortly to become a
     customer, client or patient of the Company, AmeriPath or any Affiliate of
     the Company or AmeriPath, except that it shall not be a violation of this
     Agreement for the Employee to perform pathology services in the Restricted
     Territory during the Restricted Period (i) as an employee of a local,
     federal or state government or agency; (ii) in performing the Employee's
     duties as a member of the United States military services or the National
     Guard; or (iii) on a locum tenens basis. Further, provided that the
     following activities do not interfere with the Employee's full time service
     to the Jacksonville Division of AmeriPath, nothing contained in this
     Employment Agreement shall prohibit the Employee from (i) performing
     consulting services to persons who are not customers, clients or patients
     of the Company, AmeriPath or any Affiliate of the Company or AmeriPath,
     including the entities of Baxter, Johnson & Johnson, Immucar, Serollogicils
     and Coral Therapeutics, Etc., (ii) providing expert testimony, opinion
     consultation, (iii) participating in non-pathology related businesses; and
     (iv) holding a passive stock interest in Laboratory Physicians, St.
     Petersburg, P.A. or any successor thereof and receiving payments in respect
     of such stock interest.

          (c)  As used in this Agreement, the term "RESTRICTED PERIOD" shall
mean and include the period during which the Employee is Employed by the
Company, or any Affiliate of the Company and a period of two (2) years from the
effective date of the Employee's termination of employment with the Company or
such Affiliate of the Company; provided, however, that the Restricted Period
shall be reduced to zero (0) days from the effective date of the Employee's
termination of employment with the Company or such Affiliate of the Company in
the event that (i) the Employee's employment is terminated without cause, or
(ii) the Company elects not to renew this Employment Agreement as provided
herein.

          (d)  The Employee further agrees that during the Restricted Period the
Employee will not, directly or indirectly, (1) solicit the employment of any
employee, agent or consultant of the Company, or an Affiliate of the Company,
who was such at any time during the twelve (12) months preceding the Employee's
termination of employment with the Company, or (2) induce any employee of the
Company, or any Affiliate of the Company, to leave the employ of the Company (or
of such Affiliate), or (3) solicit any payer contracts from any payor of the
Company (or of an Affiliate of the Company), or otherwise interfere with any
such payor, or (4) solicit or otherwise interfere with any referral sources of
the Company or any Affiliate of the Company, unless in each case the Employee
obtains the prior written consent of the Company.

          (e)  In recognition of the substantial nature of such potential
damages, the Employee agrees that the Company shall be entitled to specific
performance of this provision, and to injunctive and other equitable relief, and
that the Employee will be responsible for the payment of court costs and
reasonable attorneys' fees incurred by the Company in seeking enforcement the
covenant set forth herein. This Section 20 shall survive the termination of this
Agreement and the termination of the Employee's employment with the Company. The
Employee acknowledges that the enforcement of this covenant is not contrary to
the public health, safety, or welfare in that the population in the areas set
forth herein is adequately served

                                       14
<Page>

??qualified pathologists. Further, the Employee acknowledges that the Employee's
breach of ??s covenant will cause irreparable injury to the Company.

     21.  CONFIDENTIALITY.

          (a)  ACKNOWLEDGEMENT. The Employee acknowledges and agrees that in the
course of rendering services to the Company and its clients, the Employee will
have access to ?? will become acquainted with confidential and proprietary
information about the professional, business and financial affairs of the
Company, its Affiliates and its patients, clients and customers, and that the
Employee may have contributed to or may in the future contribute to such
information. The Employee further recognizes that the Employee is being employed
as a ?? employee, that the Company is engaged in a highly competitive business,
and that the success of the Company in the marketplace and business depends upon
its goodwill and ??utation for integrity, quality and dependability. The
Employee recognizes that in order to ??ard the legitimate interests of the
Company it is necessary for the Company to protect all such confidential and
proprietary information, goodwill and reputation.

          (b)  PROPRIETARY INFORMATION. In the course of the Employee's service
to the Company, the Employee may have access to confidential know-how, business
documents or information, marketing data, client lists and trade secrets which
are confidential. Such information shall hereinafter be called "Proprietary
Information" and shall include any and all terms enumerated in the preceding
sentence which come within the scope of the business activities of the Company
as to which the Employee has had or may have access, whether previously
existing, now existing or arising hereafter, whether or not conceived or
developed by ??ers or by the Employee alone or with others during the period of
his service to the Company, and whether or not conceived or developed during
regular working hours. "Proprietary Information" shall not include (a) any
information which is in the public domain during the period of service by the
Employee or becomes public thereafter, provided such information is not ?? the
public domain as a consequence of disclosure by the Employee in violation of
this agreement, and (b) any information not considered confidential information
by similar enterprises operating in the clinical or anatomical laboratory
industry or otherwise in the ordinary course.

          (c)  FIDUCIARY OBLIGATIONS. The Employee agrees and acknowledges that
the Proprietary Information is of critical importance to the Company and a
violation of this Section ?? will seriously and irreparably impair and damage
the Company's businesses. The Employee therefore agrees, while he is an employee
of the Company and at all times thereafter, to keep all Proprietary Information
strictly confidential.

          (d)  NON-DISCLOSURE. Except as required by law or order of any court
or Governmental entity or in connection with the proper performance of his
duties hereunder, the employee shall not disclose, directly or indirectly
(except as required by law), any Proprietary Information to any person other
than (a) the Company, (b) persons who are authorized employees of the Company at
the time of such disclosure, (c) such other persons, including prospective

                                       15
<Page>

investors or lenders, to whom the Employee has been instructed to make
disclosure by the Company's Board of Directors, or (d) the Employee's counsel,
which counsel shall keep all Proprietary Information confidential (in the case
of clauses (b) and (c), only to the extent required in the course of the
Employee's service to the Company). Upon any termination of the Employee's
employment hereunder, the Employee shall deliver to the Company all notes,
letters, documents, tapes, discs, recorded data and records which may contain
Proprietary Information which are then in the Employee's possession or control
and shall not retain, use, or make any copies, summaries or extracts thereof.

     22.  INVALID PROVISION. The invalidity or unenforceability of any provision
of this agreement shall not affect the validity or enforceability of any other
provision of this agreement. The Employee and the Company agree and acknowledge
that the provisions of Sections 20 and 21 are material and of the essence to
this Agreement, If the scope of any restriction or covenant contained herein
should be or become too broad or extensive to permit enforcement thereof to its
fullest extent, then such restriction or covenant shall be enforced to the
maximum extent permitted by law, and the Employee hereby consents and agrees
that (a) it is the parties intention and agreement that the covenants and
restrictions contained herein be enforced ?? written, and (b) in the event a
court of competent jurisdiction should determine that any restriction or
covenant contained herein is too broad or extensive to permit enforcement
thereof ?? its fullest extent, the scope of any such restriction or covenant may
be modified accordingly in ??y judicial proceeding brought to enforce such
restriction or covenant, but should be modified ?? permit enforcement of the
restrictions and covenants contained herein to the maximum extent the court, in
its judgment, will permit.

     23.  APPLICABLE LAW. This Agreement shall be governed by and construed and
enforced in accordance with the laws of the State of Florida.

     24.  BINDING EFFECT; ASSIGNMENT. This Agreement shall inure to the benefit
of and ??nding on the Employee and the Company and the Employee's and the
Company's respective ??eirs, personal representatives, successors and assigns;
HOWEVER, that the Employee shall have no right to assign the Employee's rights
or duties under this contract to any other person. In the event of the Company's
sale, merger or consolidation, the Employee specifically agrees that the Company
may assign the Company's rights and obligations hereunder to the Company's
successor, assign or purchaser. In addition, and in any event, the Company may,
at any time, assign the Company's rights and obligations under this Agreement to
any Person that is an affiliate of the Company or to any Person which, after any
such assignment, employs at least) ??% of the physician employees employed by
(the Company immediately prior to the assignment, PROVIDED, that any successor
shall expressly assume, and AmeriPath, Inc. (the Company's parent), or its
successor, shall guaranty, the obligations hereunder.

     25.  NOTICES. Any required notice under this Agreement shall be made and
delivered ?? writing. Delivery of such notice shall be made (x) if to the
Company, to AmeriPath, Inc., ??289 Garden Road, Suite 200, Riviera Beach,
Florida 33404, Attention: President; and (y) if to the Employee, to the last
known residential address of Employee as listed in the Company's

                                       16
<Page>

employment records. Delivery of such notice shall be deemed to have occurred (i)
in the case of hand delivery, when personally delivered to the other party at
such party's address; or (ii) in the case of mailing, three (3) days after such
notice has been deposited in the United States mails, postage prepaid, by
certified or registered mail, with return receipt requested, and addressed to
the other party as set forth in this Agreement; or (iii) in any other case, when
actually received by the other party. Either party may change the address to
which notices are to be given by giving written notice of such change to the
other party in accordance with this Section 25.

     26.  ATTORNEYS' FEES AND COSTS. In any action, suit or proceeding to
enforce the terms and conditions of this Agreement, the prevailing party shall
receive and the unsuccessful party shall pay all costs, fees and expenses,
including reasonable attorney's costs, fees and expenses, incurred in enforcing
its rights under this Agreement, including costs, expenses and fees with respect
to trials, appeals and collection.

     27.  AMENDMENT. This Agreement may not be modified or amended in any manner
other than in a written document signed by both parties.

     28.  LEGISLATIVE LIMITATIONS. Notwithstanding any other provision of this
Agreement, if the governmental agencies (or their representatives) which
administer Medicare or Medicaid, or any other government third party payor
program, or any other federal, state or local government or agency passes;
issues or promulgates any law, rule, regulation, standard or interpretation at
any time while this Agreement is in effect which prohibits, restricts, limits or
in any way adversely changes the method or amount of reimbursement, compensation
or payment for services rendered by the Company (or its physician employees)
under this Agreement, or which otherwise adversely affects either the Employee's
or the Company's rights or obligations hereunder, then (i) the parties hereto
shall, promptly upon notice from either party, negotiate in good faith to amend
this Agreement to provide for such reimbursement, compensation or payment for
services in a manner consistent with any prohibition, restriction, limitation
and/or which takes into account any adverse change in reimbursement,
compensation or payment for physician services, and (ii) in the event the
parties are unable to reach agreement within ten (10) days after said notice is
given, the Company shall assign this Agreement (and the Company's rights and
obligations hereunder) to an Affiliate, (if such assignment cures or
substantially alleviates such prohibition, restriction, limitation or adverse
change) or terminate this Agreement and the rights and obligations of each of
the parties hereunder, as of midnight on such tenth (10th) day.

     29.  MISCELLANEOUS.

          (a)  EXCLUSIVE AGREEMENT. The terms of the Employee's employment with
the Company are exclusively governed by the terms of this Agreement. Any and all
prior agreements, arrangements, promises, representations, discussions or
understandings which either of the parties may have had concerning the
Employee's employment are hereby canceled, superseded and of no further force or
effect.

                                       17
<Page>

          (b)  CONFIDENTIALITY. The Company and the Employee acknowledge and
agree that this Agreement and each of the provisions hereof shall be treated as
confidential and, except to the extent required by applicable law or regulations
or order of any court or governmental entity, or as deemed reasonably necessary
by the Company to facilitate due diligence in connection with acquisitions or
financings, neither the Employee nor the Company shall disclose the terms of the
Agreement, or provide copies hereof, to any third party (other than counsel or
advisers) without the prior written consent of the other party.

          (c)  DEFINITIONS. (1) "AFFILIATE" shall mean and include, with regard
to any Person, (a) any Person, directly or indirectly, controlled by, under
common control of, or controlling such Person, (b) any Person, directly or
indirectly, in which such Person holds, of record or beneficially, five percent
or more of the equity or voting securities, (c) any Person that holds, of record
or beneficially, five percent or more of the equity or voting securities of such
Person, (d) any Person that, through Contract, relationship or otherwise, exerts
a substantial influence on the management of such Person's affairs, (e) any
Person that, through Contract, relationship or otherwise, is influenced
substantially in the management of their affairs by such Person, or (f) any
director, officer, partner or individual holding a similar position in respect
of such Person.

               (2)  "COMPANY" Where a provision contained in this Agreement
requires or permits the action, adoption, review or approval of, or provides for
certain power, authority or judgment of, the Company, such action, adoption,
review, approval, power, authority or judgment may be exercised, taken or made
by an Affiliate of the Company, or by AmeriPath or its Affiliates, if such
Affiliate of the Company, or AmeriPath or its Affiliates, is required or
permitted to exercise, take or make such action, adoption, review, approval,
power, authority or judgment through or by virtue of a Contract to which the
Company or the Employee is a party or otherwise.

               (3)  "CONTRACT" means and includes any agreement, contract,
commitment, instrument or other binding arrangement, obligation or
understanding, whether written or oral.

               (4)  "PERSON" means and includes any corporation, partnership,
joint venture, company, syndicate, organization, association, trust, entity,
authority or natural person.

          (d)  CONSENT TO JURISDICTION; SERVICE OF PROCESS. The parties hereby
irrevocably submit to the jurisdiction of the state or federal courts wherein
lies Duval County in connection with any suit, action or other proceeding
arising out of or relating to this Agreement and hereby agrees not to assert, by
way of motion, as a defense, or otherwise in any such suit, action or proceeding
that the suit, action or proceeding is brought in an inconvenient forum, that
the venue of the suit, action or proceeding is improper or that this Agreement
or the subject matter hereof may not be enforced by such courts.

                                       18
<Page>

          (e)  HEADINGS. The article, section and other headings contained in
this Agreement are for reference purposes only and do not affect in any way the
meaning or interpretation of any or all of the provisions of this Agreement.

          (f)  PRONOUNS AND PLURALS. Whenever the context may require, any
pronoun used in this Agreement shall include the corresponding masculine,
feminine, or neuter forms, and the singular forms of nouns, pronouns, and verbs
include the plural and vice versa.

          (g)  CONSTRUCTION. The parties acknowledge that each party has
reviewed and revised this Agreement and that the normal rule of construction to
the effect that any ambiguities are to be resolved against the drafting party
shall not be employed in the interpretation of this Agreement.

          (h)  COUNTERPARTS. This Agreement may be executed in two or more
counterparts, each of which shall be deemed an original, but all of which
together shall constitute one and the same instrument.

     IN WITNESS WHEREOF, the parties hereto have made and entered into this
Agreement as of the date first hereinabove set forth.

                                         AMERIPATH

                                         By: /s/ Robert P. Wynn
                                             --------------------------------
                                             Robert P. Wynn, Vice President

                                         EMPLOYEE:

                                         /s/ Dennis M. Smith, Jr.
                                         ------------------------------------
                                         DENNIS M. SMITH, JR., M.D.

                                       19
<Page>

                AMENDMENT TO & ASSIGNMENT OF EMPLOYMENT AGREEMENT

          THIS AMENDMENT TO & ASSIGNMENT OF EMPLOYMENT AGREEMENT ("Amendment and
Assignment") is made this 11th day of June, 2001, by and between AMERIPATH
FLORIDA, INC. (the "Company"), AMERIPATH, INC. ("AmeriPath, Inc.") and DENNIS M.
SMITH, JR., M.D. (the "Executive").

                               W I T N E S S E T H

          WHEREAS, the Executive and the Company entered into an Employment
Agreement dated December 1, 1997 (the "Employment Agreement"), pursuant to which
the Executive has been providing services; and

          WHEREAS, the Executive and the Company wish to amend the Employment
Agreement to reflect changes in the Executive's duties, level of responsibility
and compensation; and

          WHEREAS, the Company wishes to assign the Employment Agreement to
AmeriPath, Inc.

          NOW, THEREFORE, in consideration of the mutual promises contained
herein, the Executive's continued employment and other good and valuable
consideration, the receipt and sufficiency of which is hereby acknowledged, the
Executive and the Company agree as follows:

          1.   RECITALS. The above recitals are true and correct and are
incorporated herein by this reference.

          2.   ASSIGNMENT. Pursuant to Section 24 of the Employment Agreement,
the Company hereby assigns the Employment Agreement to its parent, AmeriPath,
Inc. The Executive consents to and accepts such assignment. AmeriPath, Inc.
accepts such assignment and assumes and guarantees the obligations of the
Company under the Employment Agreement. In accordance with this assignment, the
term "Company", in the Employment Agreement, shall, hereafter, refer to
AmeriPath, Inc.

          3.   POSITION. The first sentence in Section 1 of the Employment
Agreement is amended to read: "Subject to the terms and conditions of this
Agreement, the Company shall employ the Executive to render professional
services to the Company as its Executive Vice President of Genomic Strategies
and Chief Medical Officer, and the Executive accepts such employment and such
position." The Executive's title, in the second sentence of Section 3 of the
Employment Agreement is changed from "Medical Director of the Jacksonville
Division" to "Executive Vice President of Genomic Strategies and Chief Medical
Officer".

          4.   SALARY. The Executive's salary, as set forth in Section 7 of the
Employment Agreement, is changed from "$250,000" to "$350,000" effective January
1, 2001.

          5.   STOCK OPTIONS. The last two sentences in Section 7 of the
Employment Agreement are deleted and the following language is substituted
therefore;

<Page>

          "During the Term hereunder, and subject to the execution of any other
applicable agreements, the Executive shall be eligible on an annual basis to
receive options (the "STOCK OPTIONS") to purchase common stock (the "COMMON
STOCK") of the Company, the amount to be determined by the Chairman of the Board
and CEO (the "CHAIRMAN") of the Company based upon the Executive's performance
and services rendered to the Company, and subject to the approval by both the
Compensation Committee and the Board at their regular annual review of executive
performance. If and to the extent awarded, the Stock Options shall be granted
under (and therefore subject to all terms of) the Company's stock option plan
(the "STOCK OPTION PLAN") and pursuant to the terms of a certain stock option
agreement (the "OPTION AGREEMENT") to be entered into by and between the
Executive and the Company. In addition, during the Term, the Executive shall be
eligible to be granted additional options under the Company's Stock Option Plan.
The number, if any, of additional options and terms and conditions thereof shall
be determined by the Committee appointed pursuant to the Stock Option Plan, or
by the Board of Directors of the Company, in its discretion and pursuant to the
Stock Option Plan. Notwithstanding any other provision of this Agreement, Option
Agreements entered into by the Executive and the Company prior to the date of
this Agreement shall remain in full force and effect."

          6.   TERMINATION. The following subsection (d) is added to Section 15
of the Employment Agreement:

          (d)  CHANGE IN CONTROL OF THE COMPANY.

               (1)  In the event that a Change in Control [as defined in
subsection (2) of this Section 6 (d)] in the Company shall occur during the Term
of Employment, the Company shall accelerate the vesting of all AmeriPath Stock
Options which have been granted to the Executive but are unvested, so that the
unvested shares are one hundred (100) percent vested on the date of the Change
in Control. In addition, if a Change in Control of the Company occurs during the
Term of Employment, and prior to one year after the date of the Change in
Control the Term is terminated by the Company without Cause pursuant to Section
15 (c) hereof, or the Company requires the Executive to be based at any office
or location more than twenty-five (25) miles from that in which the Executive
was working on the date of the Change in Control and the Executive thereby
elects to terminate this Agreement, the Company shall (i) pay to the Executive
any accrued and unpaid Base Salary through the effective date of the
termination, (ii) pay to the Executive, within 30 days of the termination of his
employment hereunder, a lump sum payment equal to one times the Executive's
annual Base Salary, and (iii) accelerate the vesting of all AmeriPath Stock
Options which have been granted to the Executive but are unvested, so that the
unvested shares are one hundred (100) percent vested as of the Executive's
Termination Date. The Company shall have no further liability hereunder (other
than for reimbursement for reasonable business expenses incurred prior to the
date of termination and payment of compensation for accrued and unused vacation
days).

               (2)  For purposes of this Agreement, the term "CHANGE IN CONTROL"
shall mean:

                    (A)  Approval by the shareholders of the Company of (x) a
reorganization, merger, consolidation or other form of corporate transaction or
series of

                                        2
<Page>

transactions, in each case, with respect to which persons who were the
shareholders of the Company immediately prior to such reorganization, merger or
consolidation or other transaction do not, immediately thereafter, own more than
50% of the combined voting power entitled to vote generally in the election of
directors of the reorganized, merged or consolidated company's then outstanding
voting securities, in substantially the same proportions as their ownership
immediately prior to such reorganization, merger, consolidation or other
transaction, or (y) a liquidation or dissolution of the Company or (z) the sale
of all or substantially all of the assets of the Company (unless such
reorganization, merger, consolidation or other corporate transaction,
liquidation, dissolution or sale is subsequently abandoned);

                    (B)  Individuals who, as of the Commencement Date of this
Agreement, constitute the Board (the "INCUMBENT BOARD") cease for any reason to
constitute at least a majority of the Board, provided that any person becoming a
director subsequent to the Commencement Date of this Agreement whose election,
or nomination for election by the Company's shareholders, was approved by a vote
of at least a majority of the directors then comprising the Incumbent Board
(other than an election or nomination of an individual whose initial assumption
of office is in connection with an actual or threatened election contest
relating to the election of the Directors of the Company) shall be, for purposes
of this Agreement, considered as though such person were a member of the
Incumbent Board; or

                    (C)  the acquisition (other than by or from the Company) by
any person, entity or "group", within the meaning of Section 13(d)(3) or
14(d)(2) of the Securities Exchange Act, of beneficial ownership within the
meaning of Rule 13-d promulgated under the) Securities Exchange Act of 50% or
more of either the then outstanding shares of the Company's Common Stock or the
combined voting power of the Company's then outstanding voting securities
entitled to vote generally in the election of directors [(hereinafter referred
to as the ownership of a "CONTROLLING INTEREST") excluding, for this purpose,
any acquisitions by (i) the Company or its Subsidiaries, (ii) any person, entity
or "group" that as of the Commencement Date of this Agreement owns beneficial
ownership (within the meaning of Rule l3d-3 promulgated under the Securities
Exchange Act) of a Controlling Interest or (iii) any Executive benefit plan of
the Company or its Subsidiaries].

          7.   NONCOMPETITION AND NON-SOLICITATION AGREEMENT. The word "or," is
added to the end of Section 20.(b)(2) and the following Section 20.(b)(3) is
added to the Employment Agreement:

               (3)  directly or indirectly, engage in or have any interest in
any sole proprietorship, corporation, company, partnership, association, venture
or business or any other person or entity that directly or indirectly (or
through any affiliated entity) competes with the Company's business (for
purposes of this Agreement, any business that engages in the management or
provision of anatomic pathology diagnostic services (whether through physician
practices, laboratories, hospitals, medical or surgery centers or otherwise)
shall be deemed to compete with the Company's business); provided that such
provision shall not apply to the Executive's ownership of common stock of the
Company or the acquisition by the Executive, solely as an investment, of
securities of any issuer that are registered under Section 12(b) or 12(g) of the
Securities Exchange Act of 1934, as amended, and that are listed or admitted for
trading on any United States national securities exchange or that are quoted on
the National

                                        3
<Page>

Association of Securities Dealers Automated Quotations System, or any similar
system or automated dissemination of quotations of securities prices in common
use, so long as the Executive does not control, acquire a controlling interest
in or become a member of a group which exercises direct or indirect control of,
more than five percent (5.0%) of any class of capital stock of such corporation.

          8.   CONFLICTING TERMS & SURVIVAL OF AGREEMENT. Except as specifically
set forth herein, the Employment Agreement shall remain in full force and
effect. In the event the terms of this Amendment and Assignment shall conflict
with the terms of the Employment Agreement, the terms of this Amendment and
Assignment shall control.

          9.   COUNTERPARTS. This Amendment and Assignment may be executed in
any number of counterparts, each of which shall be deemed to be an original, and
all of which together constitute one documents.

          10.  FINAL AGREEMENT. The Employment Agreement, as amended by this
Amendment and Assignment, shall constitute the final agreement between the
parties hereto and supercedes any prior or contemporaneous agreement or
representation, oral or written, among them with respect to the matters set
forth in the Employment Agreement and this Amendment and Assignment.

          11.  CONFIDENTIALITY. The Executive shall not disclose to any person
or entity any information whatsoever regarding the terms of this Amendment and
Assignment or the Agreement. Such limitation does not include Executive's
disclosure to any attorneys, accountants and professional tax advisers with whom
Executive chooses to consult or seek advice regarding Executive's consideration
of and decision to execute this Amendment and Assignment.

IN WITNESS WHEREOF, the parties have executed this Amendment and Assignment on
the date set forth above.

AMERIPATH FLORIDA, INC.

AMERIPATH, INC.

By: /s/ James C. New
   ---------------------------------
        James C. New
        Chairman and Chief Executive Officer

EXECUTIVE

    /s/ Dennis M. Smith, Jr.
   ---------------------------------
        Dennis M. Smith, Jr., M.D.

                                        4
<Page>

                                 AMENDMENT NO. 2
                             TO EMPLOYMENT AGREEMENT

          THIS AMENDMENT NO. 2 TO EMPLOYMENT AGREEMENT ("AMENDMENT") is made
this 8 day of December 2002, by and between AMERIPATH, INC., a Delaware
corporation (the "COMPANY") and DENNIS M. SMITH, JR., M.D. (the "EXECUTIVE").

          WHEREAS, the Executive is currently employed by the Company pursuant
to an Employment Agreement dated December 1, 1997 (as amended on June 11, 2001,
the "AGREEMENT");

          WHEREAS, the Company, Amy Holding Company (the "PARENT"), and Amy
Acquisition Corp. have entered into an Agreement and Plan of Merger, dated on or
about December 8, 2002 (the "MERGER AGREEMENT"); and

          WHEREAS, in connection with the Merger Agreement, the Company and the
Executive wish to amend the Agreement.

          NOW, THEREFORE, in consideration of the Executive's continued
employment with the Company and other good and valuable consideration, the
receipt and sufficiency of which is hereby acknowledged, the Company and the
Executive agree as follows:

          1.   EFFECTIVE DATE. This Amendment shall become effective on the
closing date of the transactions contemplated by the Merger Agreement (the
"EFFECTIVE DATE").

          2.   STOCK OPTIONS. On the Effective Date, the Executive will be
granted options to purchase at a $1 per share exercise price that number of
shares of common stock of the Parent equal to 0.25% of the Parent's common stock
outstanding on a fully-diluted basis as of the Effective Date, half of which
shall be granted in the form of a time-based option pursuant to an Time-Based
Option Agreement substantially in the form of EXHIBIT A hereto and half of which
shall be granted in the form of a performance-based option pursuant to a
Performance-Based Stock Option Agreement substantially in the form of EXHIBIT B
hereto (it being understood that (i) such 0.25% amount has been determined
assuming that, on the Effective Date, Welsh, Carson, Anderson & Stowe IX, L.P.
and its affiliated investors (collectively, "WCAS") will provide the equity and
debt financing contemplated in the financing commitment letters for the
transactions contemplated by the Merger Agreement and (ii) if WCAS is required
to provide additional equity financing to Parent in order to consummate the
transactions contemplated by the Merger Agreement, the equity issued to WCAS in
connection with such additional financing will dilute such 0.25% amount on the
same basis as other holders of Parent common equity securities).

<Page>

          3.   AMENDMENTS.

          (a)  The last two sentences of Section 7 are deleted in their
entirety.

          (b)  Section 15(d) of the Agreement is deleted in its entirety and
replaced with the following:

     (d)  CHANGE IN CONTROL.

               (1)  If, prior to the one-year anniversary of the closing of the
     transactions contemplated by that certain Agreement and Plan of Merger,
     dated on or about December 8, 2002, among AmeriPath, Inc., Amy Holding
     Company, and Amy Acquisition Corp., (i) the Term of Employment is
     terminated by the Company without Cause pursuant to Section 15(c) hereof or
     (ii) the Company requires the Executive to be based at any office or
     location more than twenty-five (25) miles from that in which the Executive
     was based at the time this Amendment was executed (except for travel
     reasonably required in the performance of the Executive's duties and
     responsibilities under the Agreement) and the Executive elects to terminate
     the Term of Employment as a result, a "Change of Control Termination" shall
     be deemed to have occurred.

               (2)  In the event of a "Change of Control Termination" under
     paragraph (1) of this paragraph (d), the Company shall (i) pay to the
     Executive any accrued and unpaid Base Salary through the effective date of
     the termination and (ii) pay to the Executive, within 30 days of the
     termination of his employment hereunder, a lump sum payment equal to one
     times the Executive's annual Base Salary.

               The Company shall have no further liability hereunder (other than
     for reimbursement for reasonable business expenses incurred prior to the
     date of termination and payment of compensation for accrued and unused
     vacation days).

          4.   ACKNOWLEDGEMENT. The Company shall use its best efforts to cause
its own shareholders and the shareholders of the Parent, as applicable,
immediately prior to a Change of Control (as defined in the Executive's
Time-Based Stock Option Agreement with AmeriPath Holdings, Inc.) to approve any
payment or benefit (the "PAYMENT") that the Company and/or the Parent is
required to make to the Executive upon or in connection with the occurrence of a
Change of Control of the Company or the Parent in a manner that satisfies
Section 280G(b)(5)(B) of the Internal Revenue Code of 1986, as amended, and the
regulations promulgated thereunder.

          5.   CONFLICTING TERMS AND SURVIVAL OF AGREEMENT. Except as
specifically set forth herein, the Agreement shall remain in full force and
effect. In the event the terms of this Amendment shall conflict with the terms
of the Agreement, the terms of this Amendment shall control.

<Page>

          6.   COUNTERPARTS. This Amendment may be executed in any number of
counterparts, each of which shall be deemed to be an original, and all of which
together constitute one document.

          7.   FINAL AGREEMENT. The Agreement, as amended by this Amendment,
constitutes the final agreement between the parties hereto and supercedes any
prior or representation, oral or written, among them with respect to the matters
set forth in the Agreement and this Amendment.

                  [Remainder of Page Intentionally Left Blank]

<Page>

          IN WITNESS WHEREOF, the parties have executed this Amendment on the
date set forth above.

                                              AMERIPATH, INC.

                                              By:  /s/ James C. New
                                                   ------------------------
                                                   James C. New
                                                   Chairman and Chief Executive
                                                   Officer

                                              EXECUTIVE:

                                                   /s/ Dennis M. Smith, Jr.
                                              ----------------------------------
                                                  Dennis M. Smith, Jr., M.D.

<Page>

                                 AMENDMENT NO. 3
                             TO EMPLOYMENT AGREEMENT

          THIS AMENDMENT NO. 3 TO EMPLOYMENT AGREEMENT is made this 26th day of
March 2003, by and between AMERIPATH, INC., a Delaware corporation (the
"COMPANY") and DENNIS M. SMITH, JR., M.D. (the "EXECUTIVE").

          WHEREAS, the Executive is currently employed by the Company pursuant
to an Employment Agreement, dated December 1, 1997, as amended June 11, 2001,
and further amended December 8, 2002 (the "AGREEMENT");

          WHEREAS, the second amendment to the Agreement, dated December 8, 2002
("AMENDMENT NO. 2"), contemplated that the Executive would be granted options to
purchase capital stock of the Company at an exercise price of $1.00 per share
upon the closing date of the transactions contemplated by the Merger Agreement,
dated December 8, 2002 (the "MERGER AGREEMENT"), among the Company, Amy Holding
Company and Amy Acquisition Corp.;

          WHEREAS, the Executive and the Company have agreed that such options
will actually be issued at $6.00 upon the closing date of such transactions, and
as such, the Executive and the Company have agreed to further amend the
Agreement to reflect such revised exercise price;

          NOW THEREFORE, in consideration of the Executive's continued
employment with the Company and other good and valuable consideration, the
receipt and sufficiency of which is hereby acknowledged, the Company and the
Executive agree as follows;

          1.   EFFECTIVE DATE. This Amendment No. 3 shall become effective on
the closing date of the transactions contemplated by the Merger Agreement.

          2.   AMENDMENT. The reference to "$1" as the exercise price of the
options to be granted the Executive pursuant to Section 2 of Amendment No. 2 is
hereby deleted and replaced with a reference to "$6" as the exercise price for
such options.

          3.   CONFLICTING TERMS AND SURVIVAL OF AGREEMENT. Except as
specifically set forth herein, the Agreement shall remain in full force and
effect. In the event the terms of this Amendment No. 3 shall conflict with the
terms of the Agreement, the terms of this Amendment No. 3 shall control.

          4.   COUNTERPARTS. This Amendment may be executed in any number of
counterparts, each of which shall be deemed to be an original, and all of which
together constitute one document.

          5.   FINAL AGREEMENT. The Agreement, as amended by this Amendment
No. 3, constitutes the final agreement between the parties hereto and supercedes
any prior representation, oral or written, among them with respect to the
matters set forth in the Agreement and this Amendment No. 3.

<Page>

          6.   GOVERNING LAW. This Amendment No. 3 shall be governed by and
construed and enforced in accordance with the laws of the State of Florida,
without reference to principles of conflict of laws.

                  [Remainder of Page Intentionally Left Blank]

<Page>

          IN WITNESS WHEREOF, the parties have executed this Amendment on the
date set forth above.

                                       AMERIPATH, INC.

                                       By:  /s/ James C. New
                                            -----------------------------------
                                            James C. New
                                            Chairman and Chief Executive Officer

                                       EXECUTIVE

                                            /s/ Dennis M. Smith, Jr.
                                       ----------------------------------------
                                       Dennis M. Smith, Jr., M.D.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00051-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00051-of-00352.parquet"}]]